_MEMBER_data_imp_1 - 1.8-2.2,_MEMBER_data_imp_1 - 4.5-5.5,_MEMBER_data_imp_1 - 9.0-11.0,_LogP_data_imp_1 - 1.8-2.2,_LogP_data_imp_1 - 4.5-5.5,_LogP_data_imp_1 - 9.0-11.0,GO,Description,_PATTERN_,_RANK_,GiniIndex
1,1,1,-6,-4.1,-4.5,GO:0030879,mammary gland development,M111,3,0
1,1,1,-3.2,-3.1,-2,R-HSA-168142,Toll Like Receptor 10 (TLR10) Cascade,M111,3,0
1,1,1,-14,-4.8,-5.5,GO:0009792,embryo development ending in birth or egg hatching,M111,3,0
1,1,1,-5.3,-4.3,-3,GO:0050867,positive regulation of cell activation,M111,3,0
1,1,1,-2.3,-5.5,-3.3,R-HSA-8878166,Transcriptional regulation by RUNX2,M111,3,0
1,1,1,-7.4,-6.2,-2.8,GO:0050778,positive regulation of immune response,M111,3,0
1,1,1,-5.4,-4.5,-3.6,GO:0010001,glial cell differentiation,M111,3,0
1,1,1,-2.6,-3.6,-3.8,R-HSA-8878159,Transcriptional regulation by RUNX3,M111,3,0
1,1,1,-4.2,-2.1,-4.4,M17200,SA B CELL RECEPTOR COMPLEXES,M111,3,0
1,1,1,-2.8,-2.4,-2.8,WP585,Interferon type I signaling pathways,M111,3,0
1,1,1,-5.2,-9.2,-8,R-HSA-449147,Signaling by Interleukins,M111,3,0
1,1,1,-8,-2.6,-2.1,M255,PID HIF1 TFPATHWAY,M111,3,0
1,1,1,-3.3,-2.9,-3.6,GO:2000106,regulation of leukocyte apoptotic process,M111,3,0
1,1,1,-6.5,-2.9,-2.4,GO:0007169,transmembrane receptor protein tyrosine kinase signaling pathway,M111,3,0
1,1,1,-4.7,-6.4,-4.1,GO:1903037,regulation of leukocyte cell-cell adhesion,M111,3,0
1,1,1,-2,-2.3,-2.8,hsa04613,Neutrophil extracellular trap formation,M111,3,0
1,1,1,-6.4,-4.1,-2.2,GO:0007610,behavior,M111,3,0
1,1,1,-5.6,-3.5,-4,GO:0048736,appendage development,M111,3,0
1,1,1,-4.2,-3.1,-3,WP4341,Non genomic actions of 1 25 dihydroxyvitamin D3,M111,3,0
1,1,1,-10,-4.9,-4.3,WP2857,Mesodermal commitment pathway,M111,3,0
1,1,1,-4,-4.8,-2.5,M195,PID CMYB PATHWAY,M111,3,0
1,1,1,-7.8,-3,-3.3,WP4666,Hepatitis B infection,M111,3,0
1,1,1,-3.4,-3.8,-2.8,GO:0050870,positive regulation of T cell activation,M111,3,0
1,1,1,-3.3,-2.3,-3,hsa04611,Platelet activation,M111,3,0
1,1,1,-3.7,-2.4,-5.3,GO:0021954,central nervous system neuron development,M111,3,0
1,1,1,-3.8,-3.5,-2.4,GO:0050728,negative regulation of inflammatory response,M111,3,0
1,1,1,-9.4,-5.7,-3.4,GO:0071396,cellular response to lipid,M111,3,0
1,1,1,-4.3,-4.2,-2.5,GO:0071216,cellular response to biotic stimulus,M111,3,0
1,1,1,-2.8,-2.4,-3.7,GO:0035115,embryonic forelimb morphogenesis,M111,3,0
1,1,1,-11,-6.5,-4.7,GO:1902895,positive regulation of miRNA transcription,M111,3,0
1,1,1,-7.5,-4.8,-4.3,GO:0060562,epithelial tube morphogenesis,M111,3,0
1,1,1,-3.2,-2.1,-3.4,M22,PID GMCSF PATHWAY,M111,3,0
1,1,1,-9.9,-7.2,-4.9,GO:0048729,tissue morphogenesis,M111,3,0
1,1,1,-4.7,-6.1,-2.2,GO:0043434,response to peptide hormone,M111,3,0
1,1,1,-3.5,-5,-5.6,GO:0042113,B cell activation,M111,3,0
1,1,1,-4.1,-4.7,-3.3,GO:1903039,positive regulation of leukocyte cell-cell adhesion,M111,3,0
1,1,1,-13,-4.5,-5.2,hsa05200,Pathways in cancer,M111,3,0
1,1,1,-6.4,-2.4,-2.5,GO:0051056,regulation of small GTPase mediated signal transduction,M111,3,0
1,1,1,-4.8,-4.1,-2.1,GO:0003205,cardiac chamber development,M111,3,0
1,1,1,-5,-8.6,-3.2,WP2840,Hair follicle development cytodifferentiation part 3 of 3,M111,3,0
1,1,1,-9.4,-11,-6.6,WP4149,White fat cell differentiation,M111,3,0
1,1,1,-2.3,-4.6,-2.4,GO:0032868,response to insulin,M111,3,0
1,1,1,-15,-4,-3.6,GO:0060322,head development,M111,3,0
1,1,1,-14,-9.6,-11,GO:0048568,embryonic organ development,M111,3,0
1,1,1,-4.2,-3.2,-3,GO:0031348,negative regulation of defense response,M111,3,0
1,1,1,-4.8,-3.1,-2.9,GO:0048872,homeostasis of number of cells,M111,3,0
1,1,1,-5.2,-7.5,-3.5,GO:0141091,transforming growth factor beta receptor superfamily signaling pathway,M111,3,0
1,1,1,-5.9,-6,-6.8,GO:1903706,regulation of hemopoiesis,M111,3,0
1,1,1,-8.6,-10,-3.4,GO:0061061,muscle structure development,M111,3,0
1,1,1,-3.3,-2.5,-6.4,R-HSA-9006335,Signaling by Erythropoietin,M111,3,0
1,1,1,-3.9,-3.9,-3.1,GO:0002293,alpha-beta T cell differentiation involved in immune response,M111,3,0
1,1,1,-3.1,-3.3,-3.7,GO:0002274,myeloid leukocyte activation,M111,3,0
1,1,1,-8.3,-8.5,-2.6,R-HSA-9031628,NGF-stimulated transcription,M111,3,0
1,1,1,-4.2,-4,-5,GO:0046631,alpha-beta T cell activation,M111,3,0
1,1,1,-9.8,-4.2,-3.8,GO:0051960,regulation of nervous system development,M111,3,0
1,1,1,-5.7,-5.1,-2.9,GO:0043583,ear development,M111,3,0
1,1,1,-14,-4.2,-3.7,GO:0007420,brain development,M111,3,0
1,1,1,-3.6,-2.3,-2.2,GO:0003231,cardiac ventricle development,M111,3,0
1,1,1,-12,-6.4,-8.3,GO:0042110,T cell activation,M111,3,0
1,1,1,-5.6,-3.5,-4,GO:0060173,limb development,M111,3,0
1,1,1,-8.4,-7.6,-7.2,GO:0008283,cell population proliferation,M111,3,0
1,1,1,-9.9,-3.4,-7.5,GO:0030217,T cell differentiation,M111,3,0
1,1,1,-4.5,-3.5,-2.1,GO:1902075,cellular response to salt,M111,3,0
1,1,1,-13,-6,-14,GO:1903131,mononuclear cell differentiation,M111,3,0
1,1,1,-10,-4.5,-4.3,GO:0001701,in utero embryonic development,M111,3,0
1,1,1,-3.1,-2.7,-4,M124,PID CXCR4 PATHWAY,M111,3,0
1,1,1,-5,-7.5,-2.3,GO:0060537,muscle tissue development,M111,3,0
1,1,1,-4.9,-2.1,-3.2,WP560,TGF beta receptor signaling,M111,3,0
1,1,1,-4.6,-3.3,-2.6,GO:0050727,regulation of inflammatory response,M111,3,0
1,1,1,-4.1,-5.8,-3.7,GO:0071559,response to transforming growth factor beta,M111,3,0
1,1,1,-2.1,-3.5,-4.5,R-HSA-9824443,Parasitic Infection Pathways,M111,3,0
1,1,1,-12,-6.2,-2.1,GO:0006366,transcription by RNA polymerase II,M111,3,0
1,1,1,-4.2,-2,-2,GO:0032526,response to retinoic acid,M111,3,0
1,1,1,-7.8,-2.1,-2.1,GO:0009952,anterior/posterior pattern specification,M111,3,0
1,1,1,-6,-6.2,-3,GO:0007517,muscle organ development,M111,3,0
1,1,1,-4.4,-3.4,-2.8,R-HSA-400253,Circadian Clock,M111,3,0
1,1,1,-4.5,-3.9,-2.2,GO:0003279,cardiac septum development,M111,3,0
1,1,1,-7.4,-4.2,-4.9,GO:0050865,regulation of cell activation,M111,3,0
1,1,1,-4.3,-2.9,-3.5,GO:0021700,developmental maturation,M111,3,0
1,1,1,-4.9,-3.1,-2.4,M164,PID ERBB1 DOWNSTREAM PATHWAY,M111,3,0
1,1,1,-3.6,-3.2,-4.7,R-HSA-983695,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,M111,3,0
1,1,1,-2.7,-4.2,-3.4,GO:1902107,positive regulation of leukocyte differentiation,M111,3,0
1,1,1,-11,-5,-11,GO:0030098,lymphocyte differentiation,M111,3,0
1,1,1,-3.4,-4.8,-2.4,WP2374,Oncostatin M signaling pathway,M111,3,0
1,1,1,-2.6,-3.5,-2.4,R-HSA-2559583,Cellular Senescence,M111,3,0
1,1,1,-3.2,-2.6,-3,M122,PID IL2 1PATHWAY,M111,3,0
1,1,1,-2.9,-4.8,-2.6,WP5373,Role of hypoxia angiogenesis and FGF pathway in OA chondrocyte hypertrophy,M111,3,0
1,1,1,-2.8,-4,-2.4,R-HSA-975155,MyD88 dependent cascade initiated on endosome,M111,3,0
1,1,1,-2.8,-5.7,-3,GO:0001709,cell fate determination,M111,3,0
1,1,1,-8.2,-2.7,-2.5,GO:1902894,negative regulation of miRNA transcription,M111,3,0
1,1,1,-4.2,-3.4,-2.2,GO:0002695,negative regulation of leukocyte activation,M111,3,0
1,1,1,-3.5,-2.1,-4.5,GO:0001649,osteoblast differentiation,M111,3,0
1,1,1,-4.7,-2.5,-2.1,GO:0040007,growth,M111,3,0
1,1,1,-2.5,-3.1,-4.5,GO:0042475,odontogenesis of dentin-containing tooth,M111,3,0
1,1,1,-3.9,-2.7,-2.1,GO:0006111,regulation of gluconeogenesis,M111,3,0
1,1,1,-3.9,-3.7,-5.5,M235,PID TCR CALCIUM PATHWAY,M111,3,0
1,1,1,-2.2,-3.2,-2,GO:0010464,regulation of mesenchymal cell proliferation,M111,3,0
1,1,1,-4.5,-2.8,-3,hsa05215,Prostate cancer,M111,3,0
1,1,1,-3.6,-7,-2.3,M290,PID IL12 STAT4 PATHWAY,M111,3,0
1,1,1,-2.4,-2.2,-2.9,GO:0007219,Notch signaling pathway,M111,3,0
1,1,1,-5.5,-7.7,-6.3,GO:0010720,positive regulation of cell development,M111,3,0
1,1,1,-3.7,-2.6,-2.9,GO:0030278,regulation of ossification,M111,3,0
1,1,1,-6.2,-5.5,-5.2,M183,PID IL6 7 PATHWAY,M111,3,0
1,1,1,-2.9,-3.3,-3.3,WP5098,T cell activation SARS CoV 2,M111,3,0
1,1,1,-3.6,-3.3,-2.2,M115,PID REG GR PATHWAY,M111,3,0
1,1,1,-2.5,-4.1,-2.6,R-HSA-166058,MyD88:MAL(TIRAP) cascade initiated on plasma membrane,M111,3,0
1,1,1,-5.5,-3.4,-2.4,GO:0048844,artery morphogenesis,M111,3,0
1,1,1,-5.5,-3.8,-2.6,hsa05169,Epstein-Barr virus infection,M111,3,0
1,1,1,-2.1,-3.5,-2.2,GO:0032663,regulation of interleukin-2 production,M111,3,0
1,1,1,-8.7,-9.8,-2.4,R-HSA-9006934,Signaling by Receptor Tyrosine Kinases,M111,3,0
1,1,1,-10,-5.7,-6.3,GO:0001944,vasculature development,M111,3,0
1,1,1,-3.8,-2.8,-3.1,GO:2000177,regulation of neural precursor cell proliferation,M111,3,0
1,1,1,-4.3,-6.4,-3.8,GO:0002764,immune response-regulating signaling pathway,M111,3,0
1,1,1,-2.4,-3.3,-4,GO:0048483,autonomic nervous system development,M111,3,0
1,1,1,-5.4,-3.8,-3.5,GO:0003151,outflow tract morphogenesis,M111,3,0
1,1,1,-2.7,-4.2,-3.4,GO:1903708,positive regulation of hemopoiesis,M111,3,0
1,1,1,-2.2,-2.4,-2.8,WP3893,Development and heterogeneity of the ILC family,M111,3,0
1,1,1,-4.4,-2.2,-3.4,GO:0060349,bone morphogenesis,M111,3,0
1,1,1,-3.3,-2.7,-4.9,M8626,SIG BCR SIGNALING PATHWAY,M111,3,0
1,1,1,-14,-4.7,-5.7,GO:0043009,chordate embryonic development,M111,3,0
1,1,1,-3.6,-5.5,-2.5,R-HSA-9664323,FCGR3A-mediated IL10 synthesis,M111,3,0
1,1,1,-3.2,-3.2,-2.6,GO:0032922,circadian regulation of gene expression,M111,3,0
1,1,1,-3.5,-2.4,-3.7,GO:0048663,neuron fate commitment,M111,3,0
1,1,1,-6.3,-4.5,-2.2,GO:0007623,circadian rhythm,M111,3,0
1,1,1,-8.7,-7.1,-3.9,GO:0007507,heart development,M111,3,0
1,1,1,-7.3,-6.8,-2.6,R-HSA-166520,Signaling by NTRKs,M111,3,0
1,1,1,-4.6,-4.3,-5,GO:0045637,regulation of myeloid cell differentiation,M111,3,0
1,1,1,-11,-3.6,-4,GO:0030900,forebrain development,M111,3,0
1,1,1,-2.4,-2.5,-3.9,GO:0030851,granulocyte differentiation,M111,3,0
1,1,1,-9.1,-5.1,-2.1,hsa04659,Th17 cell differentiation,M111,3,0
1,1,1,-11,-6.1,-6.6,GO:0001568,blood vessel development,M111,3,0
1,1,1,-4.3,-2.3,-3,GO:0001892,embryonic placenta development,M111,3,0
1,1,1,-2.5,-2.5,-2.4,WP4258,lncRNA in canonical Wnt signaling and colorectal cancer,M111,3,0
1,1,1,-6.9,-9.9,-4.9,GO:0071363,cellular response to growth factor stimulus,M111,3,0
1,1,1,-2.5,-4.1,-2.6,R-HSA-181438,Toll Like Receptor 2 (TLR2) Cascade,M111,3,0
1,1,1,-7,-3.4,-4.9,GO:0140467,integrated stress response signaling,M111,3,0
1,1,1,-5.8,-6.7,-3.2,GO:0042471,ear morphogenesis,M111,3,0
1,1,1,-4.3,-2.3,-2.2,GO:0051101,regulation of DNA binding,M111,3,0
1,1,1,-4,-3.3,-3.5,GO:0045619,regulation of lymphocyte differentiation,M111,3,0
1,1,1,-3.9,-2,-7.3,hsa04662,B cell receptor signaling pathway,M111,3,0
1,1,1,-2.2,-2.1,-2.6,GO:0007224,smoothened signaling pathway,M111,3,0
1,1,1,-3.2,-2.2,-3.4,GO:0050853,B cell receptor signaling pathway,M111,3,0
1,1,1,-9.3,-7.4,-5.7,hsa05167,Kaposi sarcoma-associated herpesvirus infection,M111,3,0
1,1,1,-6.5,-2.1,-2.8,GO:0021543,pallium development,M111,3,0
1,1,1,-2.4,-2.7,-2.6,GO:2000107,negative regulation of leukocyte apoptotic process,M111,3,0
1,1,1,-3.3,-4,-3,GO:0051250,negative regulation of lymphocyte activation,M111,3,0
1,1,1,-9,-5,-2.2,GO:0003007,heart morphogenesis,M111,3,0
1,1,1,-6.4,-5.7,-2.1,GO:1901699,cellular response to nitrogen compound,M111,3,0
1,1,1,-5.1,-3.7,-3,GO:0007498,mesoderm development,M111,3,0
1,1,1,-3.8,-4.5,-3.2,GO:0002520,immune system development,M111,3,0
1,1,1,-3.6,-4.5,-4.2,WP4844,Influence of laminopathies on Wnt signaling,M111,3,0
1,1,1,-3.6,-5,-6.8,WP286,IL 3 signaling pathway,M111,3,0
1,1,1,-3.9,-2.7,-2.1,GO:0046643,regulation of gamma-delta T cell activation,M111,3,0
1,1,1,-2.9,-4.6,-2.6,GO:0045580,regulation of T cell differentiation,M111,3,0
1,1,1,-2.2,-3.9,-3.9,R-HSA-5621481,C-type lectin receptors (CLRs),M111,3,0
1,1,1,-3.9,-3.6,-2.9,M166,PID ATF2 PATHWAY,M111,3,0
1,1,1,-5.1,-7.5,-2.9,GO:0007178,transmembrane receptor protein serine/threonine kinase signaling pathway,M111,3,0
1,1,1,-9.4,-8.6,-2.5,R-HSA-198725,Nuclear Events (kinase and transcription factor activation),M111,3,0
1,1,1,-4.7,-2.5,-2.1,GO:0048589,developmental growth,M111,3,0
1,1,1,-3.4,-2.5,-2.4,GO:0060443,mammary gland morphogenesis,M111,3,0
1,1,1,-4.6,-2,-3.1,WP4816,TGF beta receptor signaling in skeletal dysplasias,M111,3,0
1,1,1,-3,-2.8,-3.1,GO:0001764,neuron migration,M111,3,0
1,1,1,-3.6,-4.5,-4.2,M272,PID CD8 TCR DOWNSTREAM PATHWAY,M111,3,0
1,1,1,-3.2,-3.2,-5.5,R-HSA-983705,Signaling by the B Cell Receptor (BCR),M111,3,0
1,1,1,-10,-6.9,-7.7,GO:0048562,embryonic organ morphogenesis,M111,3,0
1,1,1,-4.3,-3.3,-2.4,GO:0060411,cardiac septum morphogenesis,M111,3,0
1,1,1,-17,-7.9,-5.8,GO:0140747,regulation of ncRNA transcription,M111,3,0
1,1,1,-4.1,-4,-2.4,GO:0045599,negative regulation of fat cell differentiation,M111,3,0
1,1,1,-3.5,-3.3,-2.6,GO:0002294,"CD4-positive, alpha-beta T cell differentiation involved in immune response",M111,3,0
1,1,1,-6.4,-6.2,-2.3,GO:0002697,regulation of immune effector process,M111,3,0
1,1,1,-4.9,-5.9,-5.1,R-HSA-6785807,Interleukin-4 and Interleukin-13 signaling,M111,3,0
1,1,1,-4.7,-3.7,-3.6,GO:0051962,positive regulation of nervous system development,M111,3,0
1,1,1,-4,-3.4,-2.7,GO:0072089,stem cell proliferation,M111,3,0
1,1,1,-9.2,-4.7,-7.3,WP23,B cell receptor signaling pathway,M111,3,0
1,1,1,-4,-6.2,-4.5,GO:0002252,immune effector process,M111,3,0
1,1,1,-2.9,-2.1,-3.3,GO:0035136,forelimb morphogenesis,M111,3,0
1,1,1,-15,-7.3,-6.8,GO:0035239,tube morphogenesis,M111,3,0
1,1,1,-8.4,-6,-5.6,WP706,Sudden infant death syndrome SIDS susceptibility pathways,M111,3,0
1,1,1,-8.3,-8,-2.3,GO:0030855,epithelial cell differentiation,M111,3,0
1,1,1,-8.6,-4,-5.2,GO:0048514,blood vessel morphogenesis,M111,3,0
1,1,1,-9,-2.1,-2.6,hsa04935,"Growth hormone synthesis, secretion and action",M111,3,0
1,1,1,-5.4,-4.3,-4,hsa05224,Breast cancer,M111,3,0
1,1,1,-3.2,-3.1,-2,R-HSA-168176,Toll Like Receptor 5 (TLR5) Cascade,M111,3,0
1,1,1,-8.2,-2.7,-2.5,GO:2000629,negative regulation of miRNA metabolic process,M111,3,0
1,1,1,-2.9,-2.8,-2.3,GO:0048534,hematopoietic or lymphoid organ development,M111,3,0
1,1,1,-2.9,-2.5,-2.2,GO:0043299,leukocyte degranulation,M111,3,0
1,1,1,-3.7,-3,-4.4,GO:0030183,B cell differentiation,M111,3,0
1,1,1,-4.8,-2.1,-3.3,GO:0061180,mammary gland epithelium development,M111,3,0
1,1,1,-4.8,-2.4,-2.1,R-HSA-4090294,SUMOylation of intracellular receptors,M111,3,0
1,1,1,-3.5,-4,-3.2,GO:0050851,antigen receptor-mediated signaling pathway,M111,3,0
1,1,1,-3.6,-3.8,-3,GO:0002292,T cell differentiation involved in immune response,M111,3,0
1,1,1,-14,-6.2,-3.4,GO:0009725,response to hormone,M111,3,0
1,1,1,-6.1,-6.1,-2.3,GO:0071417,cellular response to organonitrogen compound,M111,3,0
1,1,1,-2.9,-2.7,-2.7,GO:0043367,"CD4-positive, alpha-beta T cell differentiation",M111,3,0
1,1,1,-2.5,-4.1,-2.6,R-HSA-168188,Toll Like Receptor TLR6:TLR2 Cascade,M111,3,0
1,1,1,-14,-5.3,-3.2,GO:0008285,negative regulation of cell population proliferation,M111,3,0
1,1,1,-4.4,-2.5,-2.9,GO:0071695,anatomical structure maturation,M111,3,0
1,1,1,-2.3,-4.3,-2.4,GO:0046660,female sex differentiation,M111,3,0
1,1,1,-6.9,-4.3,-5.2,GO:0002694,regulation of leukocyte activation,M111,3,0
1,1,1,-3.1,-2.3,-2.8,GO:0061035,regulation of cartilage development,M111,3,0
1,1,1,-12,-11,-12,GO:0046649,lymphocyte activation,M111,3,0
1,1,1,-6,-3.5,-2.4,GO:0034101,erythrocyte homeostasis,M111,3,0
1,1,1,-2.9,-4.4,-4.1,GO:0045639,positive regulation of myeloid cell differentiation,M111,3,0
1,1,1,-4.6,-2.8,-3.7,hsa05417,Lipid and atherosclerosis,M111,3,0
1,1,1,-11,-6.5,-4.1,GO:2000630,positive regulation of miRNA metabolic process,M111,3,0
1,1,1,-3.9,-3.7,-4.4,GO:0050769,positive regulation of neurogenesis,M111,3,0
1,1,1,-2.8,-5,-5.1,GO:0030509,BMP signaling pathway,M111,3,0
1,1,1,-7.9,-4,-4.5,GO:0050767,regulation of neurogenesis,M111,3,0
1,1,1,-4.6,-2.4,-2,GO:0030324,lung development,M111,3,0
1,1,1,-10,-12,-8,GO:0045165,cell fate commitment,M111,3,0
1,1,1,-6,-3.5,-2.9,WP170,Nuclear receptors,M111,3,0
1,1,1,-3.3,-5.4,-3,M186,PID PDGFRB PATHWAY,M111,3,0
1,1,1,-6.2,-3.8,-3,GO:0060840,artery development,M111,3,0
1,1,1,-9.8,-6.8,-6.6,GO:0007389,pattern specification process,M111,3,0
1,1,1,-4.1,-5,-4.1,R-HSA-166016,Toll Like Receptor 4 (TLR4) Cascade,M111,3,0
1,1,1,-6.6,-4.1,-3.1,hsa04928,"Parathyroid hormone synthesis, secretion and action",M111,3,0
1,1,1,-4.1,-4.8,-4.8,GO:0002573,myeloid leukocyte differentiation,M111,3,0
1,1,1,-3.2,-3.1,-2,R-HSA-975871,MyD88 cascade initiated on plasma membrane,M111,3,0
1,1,1,-2.7,-2.6,-3.1,M54,PID IL12 2PATHWAY,M111,3,0
1,1,1,-9.6,-7.7,-5.2,GO:0050678,regulation of epithelial cell proliferation,M111,3,0
1,1,1,-3.9,-2.2,-2.3,GO:0048709,oligodendrocyte differentiation,M111,3,0
1,1,1,-8.4,-7.9,-8.7,GO:0030099,myeloid cell differentiation,M111,3,0
1,1,1,-2.7,-2.4,-2.8,GO:0021879,forebrain neuron differentiation,M111,3,0
1,1,1,-4.4,-2.1,-6.7,WP3945,TYROBP causal network in microglia,M111,3,0
1,1,1,-6.4,-3.9,-2.6,GO:0030218,erythrocyte differentiation,M111,3,0
1,1,1,-2.3,-2.8,-2.9,GO:0014015,positive regulation of gliogenesis,M111,3,0
1,1,1,-4.2,-2.2,-2.6,GO:0014013,regulation of gliogenesis,M111,3,0
1,1,1,-4.3,-2.7,-2.3,GO:0030111,regulation of Wnt signaling pathway,M111,3,0
1,1,1,-7,-6.4,-2.3,R-HSA-9616222,Transcriptional regulation of granulopoiesis,M111,3,0
1,1,1,-4.4,-3.5,-2.1,GO:0019221,cytokine-mediated signaling pathway,M111,3,0
1,1,1,-2.4,-2.3,-2.8,GO:0035710,"CD4-positive, alpha-beta T cell activation",M111,3,0
1,1,1,-2.1,-2.4,-2.1,WP4304,Oligodendrocyte specification and differentiation leading to myelin components for CNS,M111,3,0
1,1,1,-4.5,-2.4,-3,WP4540,Hippo signaling regulation pathways,M111,3,0
1,1,1,-12,-6.1,-5.7,GO:0007423,sensory organ development,M111,3,0
1,1,1,-4.8,-4.5,-3.3,GO:0022409,positive regulation of cell-cell adhesion,M111,3,0
1,1,1,-16,-11,-18,GO:0030097,hemopoiesis,M111,3,0
1,1,1,-5.1,-4.4,-3.1,GO:0002696,positive regulation of leukocyte activation,M111,3,0
1,1,1,-4.9,-5.7,-5,WP2849,Hematopoietic stem cell differentiation,M111,3,0
1,1,1,-2.1,-2.2,-2.1,GO:0002275,myeloid cell activation involved in immune response,M111,3,0
1,1,1,-8.8,-7.9,-3.1,R-HSA-187037,Signaling by NTRK1 (TRKA),M111,3,0
1,1,1,-7.3,-5.8,-3.5,GO:0045444,fat cell differentiation,M111,3,0
1,1,1,-9.9,-7.8,-5.5,WP236,Adipogenesis,M111,3,0
1,1,1,-4.6,-4.2,-4,WP4262,Breast cancer pathway,M111,3,0
1,1,1,-4.2,-6.2,-6.1,GO:1902105,regulation of leukocyte differentiation,M111,3,0
1,1,1,-10,-8.1,-7.8,M167,PID AP1 PATHWAY,M111,3,0
1,1,1,-3,-3.1,-2.4,GO:1902692,regulation of neuroblast proliferation,M111,3,0
1,1,1,-13,-3.8,-3.5,GO:0032870,cellular response to hormone stimulus,M111,3,0
1,1,1,-4.1,-4.3,-3.7,R-HSA-168898,Toll-like Receptor Cascades,M111,3,0
1,1,1,-7.3,-2.9,-6.6,GO:0048705,skeletal system morphogenesis,M111,3,0
1,1,1,-5.8,-3.2,-4.2,GO:0051216,cartilage development,M111,3,0
1,1,1,-5.9,-3.5,-4.9,GO:0042063,gliogenesis,M111,3,0
1,1,1,-9.3,-3.5,-3.9,hsa05161,Hepatitis B,M111,3,0
1,1,1,-2.4,-2.5,-2.8,R-HSA-8951671,RUNX3 regulates YAP1-mediated transcription,M111,3,0
1,1,1,-14,-5.4,-2.5,hsa05166,Human T-cell leukemia virus 1 infection,M111,3,0
1,1,1,-3.5,-2.8,-3.1,GO:0048565,digestive tract development,M111,3,0
1,1,1,-3.3,-3.2,-2.5,GO:0003143,embryonic heart tube morphogenesis,M111,3,0
1,1,1,-5.6,-3.5,-4,GO:0048754,branching morphogenesis of an epithelial tube,M111,3,0
1,1,1,-2.1,-2.4,-4.2,CORUM:2536,PLC-gamma-2-SLP-76-Lyn-Grb2 complex,M111,3,0
1,1,1,-9.3,-4.6,-3.9,GO:0045598,regulation of fat cell differentiation,M111,3,0
1,1,1,-4.4,-2.4,-7.3,GO:0048701,embryonic cranial skeleton morphogenesis,M111,3,0
1,1,1,-2.1,-5.6,-2.5,GO:1903038,negative regulation of leukocyte cell-cell adhesion,M111,3,0
1,1,1,-2.1,-5,-4.9,GO:0002761,regulation of myeloid leukocyte differentiation,M111,3,0
1,1,1,-3.5,-3.3,-2.6,GO:0042093,T-helper cell differentiation,M111,3,0
1,1,1,-2.1,-3.5,-4.5,R-HSA-9658195,Leishmania infection,M111,3,0
1,1,1,-9.4,-11,-5.8,GO:0070848,response to growth factor,M111,3,0
1,1,1,-5.6,-4.7,-5,GO:0061138,morphogenesis of a branching epithelium,M111,3,0
1,1,1,-8.9,-6.6,-5.7,GO:0003002,regionalization,M111,3,0
1,1,1,-10,-5.4,-7,hsa05202,Transcriptional misregulation in cancer,M111,3,0
1,1,1,-6.2,-5.4,-2.9,GO:0022612,gland morphogenesis,M111,3,0
1,1,1,-2.7,-2.6,-3.9,WP69,T cell receptor signaling pathway,M111,3,0
1,1,1,-3.6,-4.6,-2.3,WP5102,Familial partial lipodystrophy,M111,3,0
1,1,1,-16,-7.5,-6.1,GO:1902893,regulation of miRNA transcription,M111,3,0
1,1,1,-3.2,-2.2,-2.6,GO:0021602,cranial nerve morphogenesis,M111,3,0
1,1,1,-3.6,-2.5,-3.3,GO:0001890,placenta development,M111,3,0
1,1,1,-2.4,-2.9,-2.5,GO:0048486,parasympathetic nervous system development,M111,3,0
1,1,1,-6.8,-4.1,-3,GO:0090596,sensory organ morphogenesis,M111,3,0
1,1,1,-7,-6,-2.7,M2,PID SMAD2 3NUCLEAR PATHWAY,M111,3,0
1,1,1,-7.2,-3.5,-2.5,GO:0060541,respiratory system development,M111,3,0
1,1,1,-11,-4.6,-3.6,GO:0048511,rhythmic process,M111,3,0
1,1,1,-3.9,-3.9,-3.1,GO:0002287,alpha-beta T cell activation involved in immune response,M111,3,0
1,1,1,-8.3,-2.5,-5.4,GO:0021537,telencephalon development,M111,3,0
1,1,1,-4.5,-3.4,-5,GO:0030326,embryonic limb morphogenesis,M111,3,0
1,1,1,-5.6,-5.3,-4.7,WP3527,Pre implantation embryo,M111,3,0
1,1,1,-6.8,-3.7,-4.4,GO:0045664,regulation of neuron differentiation,M111,3,0
1,1,1,-4.2,-2.2,-2.5,GO:0046645,positive regulation of gamma-delta T cell activation,M111,3,0
1,1,1,-11,-4.1,-2.5,hsa05207,Chemical carcinogenesis - receptor activation,M111,3,0
1,1,1,-6.8,-4.6,-6.4,GO:0021953,central nervous system neuron differentiation,M111,3,0
1,1,1,-3.1,-2.4,-2.9,GO:0007405,neuroblast proliferation,M111,3,0
1,1,1,-8,-5.5,-3.1,hsa04658,Th1 and Th2 cell differentiation,M111,3,0
1,1,1,-4.8,-2.2,-2.1,GO:0032102,negative regulation of response to external stimulus,M111,3,0
1,1,1,-4.3,-4.2,-3.5,WP4879,Overlap between signal transduction pathways contributing to LMNA laminopathies,M111,3,0
1,1,1,-3.9,-3.3,-2.7,WP5083,Neuroinflammation and glutamatergic signaling,M111,3,0
1,1,1,-2.7,-2.2,-2.2,GO:0003281,ventricular septum development,M111,3,0
1,1,1,-4.5,-3.4,-5,GO:0035113,embryonic appendage morphogenesis,M111,3,0
1,1,1,-4.6,-6,-2.1,GO:0045667,regulation of osteoblast differentiation,M111,3,0
1,1,1,-3.5,-3.7,-3.1,GO:0035050,embryonic heart tube development,M111,3,0
1,1,1,-11,-9.2,-13,GO:0001775,cell activation,M111,3,0
1,1,1,-4.1,-4.9,-5,R-HSA-2454202,Fc epsilon receptor (FCERI) signaling,M111,3,0
1,1,1,-11,-6.5,-3.1,GO:0071345,cellular response to cytokine stimulus,M111,3,0
1,1,1,-5.4,-5.2,-5.6,GO:0001763,morphogenesis of a branching structure,M111,3,0
1,1,1,-13,-7,-8.5,GO:0001501,skeletal system development,M111,3,0
1,1,1,-2.1,-2.4,-2.1,hsa05216,Thyroid cancer,M111,3,0
1,1,1,-2.8,-3.5,-2.6,GO:0001708,cell fate specification,M111,3,0
1,1,1,-5.7,-2.4,-2.4,M279,PID RB 1PATHWAY,M111,3,0
1,1,1,-5.6,-7.6,-5.5,M60,PID NFAT TFPATHWAY,M111,3,0
1,1,1,-9,-4.4,-4.2,GO:0043010,camera-type eye development,M111,3,0
1,1,1,-3.8,-2.8,-5,M10,PID BCR 5PATHWAY,M111,3,0
1,1,1,-2.8,-4,-2.4,R-HSA-168181,Toll Like Receptor 7/8 (TLR7/8) Cascade,M111,3,0
1,1,1,-2.8,-3.2,-2.6,GO:0021783,preganglionic parasympathetic fiber development,M111,3,0
1,1,1,-13,-11,-12,GO:0045321,leukocyte activation,M111,3,0
1,1,1,-8,-3.8,-4.6,GO:0048880,sensory system development,M111,3,0
1,1,1,-4.6,-6.7,-5.2,GO:0002263,cell activation involved in immune response,M111,3,0
1,1,1,-8.1,-6,-3.4,WP366,TGF beta signaling pathway,M111,3,0
1,1,1,-2.8,-3.2,-3.7,GO:0021895,cerebral cortex neuron differentiation,M111,3,0
1,1,1,-4.5,-3.6,-2.2,GO:0050866,negative regulation of cell activation,M111,3,0
1,1,1,-3.4,-3,-5.9,GO:0097154,GABAergic neuron differentiation,M111,3,0
1,1,1,-5.8,-2.4,-2.5,GO:0045666,positive regulation of neuron differentiation,M111,3,0
1,1,1,-8.3,-3.9,-4.8,GO:0150063,visual system development,M111,3,0
1,1,1,-6.8,-3.7,-7.9,GO:1904888,cranial skeletal system development,M111,3,0
1,1,1,-5.4,-3.6,-4.2,R-HSA-2871809,FCERI mediated Ca+2 mobilization,M111,3,0
1,1,1,-2.4,-3,-2.3,GO:0038095,Fc-epsilon receptor signaling pathway,M111,3,0
1,1,1,-5.6,-4.1,-2.3,GO:0003206,cardiac chamber morphogenesis,M111,3,0
1,1,1,-2.7,-3.9,-2.3,R-HSA-168138,Toll Like Receptor 9 (TLR9) Cascade,M111,3,0
1,1,1,-4.4,-5.8,-3.9,WP3599,Transcription factor regulation in adipogenesis,M111,3,0
1,1,1,-8.7,-11,-5.5,R-HSA-1280215,Cytokine Signaling in Immune system,M111,3,0
1,1,1,-3.5,-2.7,-4,GO:0021872,forebrain generation of neurons,M111,3,0
1,1,1,-2.9,-4,-4.1,WP5218,Extrafollicular and follicular B cell activation by SARS CoV 2,M111,3,0
1,1,1,-2.5,-2.7,-3.2,M236,PID DELTA NP63 PATHWAY,M111,3,0
1,1,1,-7.4,-5.4,-2.4,GO:0001819,positive regulation of cytokine production,M111,3,0
1,1,1,-5.5,-6.5,-3.4,GO:0042472,inner ear morphogenesis,M111,3,0
1,1,1,-3.6,-7.5,-4.8,GO:0071773,cellular response to BMP stimulus,M111,3,0
1,1,1,-5.1,-3.8,-2.7,GO:0002286,T cell activation involved in immune response,M111,3,0
1,1,1,-12,-9,-5.9,GO:0045596,negative regulation of cell differentiation,M111,3,0
1,1,1,-12,-8.5,-15,GO:0002521,leukocyte differentiation,M111,3,0
1,1,1,-2.4,-2,-2.3,WP5174,Ulcerative colitis signaling,M111,3,0
1,1,1,-3.3,-4,-3.5,hsa04625,C-type lectin receptor signaling pathway,M111,3,0
1,1,1,-5.7,-4.7,-5.2,WP2064,Neural crest differentiation,M111,3,0
1,1,1,-3.6,-3.1,-4.5,hsa04650,Natural killer cell mediated cytotoxicity,M111,3,0
1,1,1,-3.6,-4.9,-2.9,GO:0071560,cellular response to transforming growth factor beta stimulus,M111,3,0
1,1,1,-2.6,-2,-2.2,GO:2000739,regulation of mesenchymal stem cell differentiation,M111,3,0
1,1,1,-3.8,-2.6,-2.9,GO:0055123,digestive system development,M111,3,0
1,1,1,-7.6,-6.5,-5.5,GO:0061448,connective tissue development,M111,3,0
1,1,1,-4,-7.8,-3.3,GO:0002250,adaptive immune response,M111,3,0
1,1,1,-5.3,-4.9,-2.4,GO:0048863,stem cell differentiation,M111,3,0
1,1,1,-4.2,-3.4,-3.2,GO:0048469,cell maturation,M111,3,0
1,1,1,-4.4,-3.1,-3.7,M151,PID AR TF PATHWAY,M111,3,0
1,1,1,-6.1,-5.1,-3.2,GO:0048839,inner ear development,M111,3,0
1,1,1,-8.7,-3.1,-2.2,R-HSA-383280,Nuclear Receptor transcription pathway,M111,3,0
1,1,1,-4.8,-4.8,-3.8,M28,PID IL4 2PATHWAY,M111,3,0
1,1,1,-6.4,-3.8,-2.1,GO:0010721,negative regulation of cell development,M111,3,0
1,1,1,-4.8,-4.4,-2.2,WP3594,Circadian rhythm genes,M111,3,0
1,1,1,-5.3,-3.7,-3.5,WP5198,Inflammatory bowel disease signaling,M111,3,0
1,1,1,-3.4,-6.2,-4.2,GO:0002429,immune response-activating cell surface receptor signaling pathway,M111,3,0
1,1,1,-4.5,-3.9,-3.8,GO:0035108,limb morphogenesis,M111,3,0
1,1,1,-4.4,-3.7,-3.5,M285,PID HNF3A PATHWAY,M111,3,0
1,1,1,-2,-4.7,-2.4,GO:0046637,regulation of alpha-beta T cell differentiation,M111,3,0
1,1,1,-12,-7.8,-7.9,GO:0048598,embryonic morphogenesis,M111,3,0
1,1,1,-4.2,-3.6,-2.1,GO:0001936,regulation of endothelial cell proliferation,M111,3,0
1,1,1,-4.2,-4.5,-3.7,GO:0051251,positive regulation of lymphocyte activation,M111,3,0
1,1,1,-6.1,-2.7,-2.7,WP5130,Th17 cell differentiation pathway,M111,3,0
1,1,1,-8.2,-2.9,-4.4,WP2858,Ectoderm differentiation,M111,3,0
1,1,1,-4.5,-3.9,-3.8,GO:0035107,appendage morphogenesis,M111,3,0
1,1,1,-9.2,-5.9,-5.7,hsa04380,Osteoclast differentiation,M111,3,0
1,1,1,-7.8,-2.1,-2.8,WP2882,Nuclear receptors meta pathway,M111,3,0
1,1,1,-6.1,-3.4,-2.5,M65,PID FRA PATHWAY,M111,3,0
1,1,1,-2.5,-3.8,-2.4,GO:0045582,positive regulation of T cell differentiation,M111,3,0
1,1,1,-4.3,-4,-3.1,GO:0060485,mesenchyme development,M111,3,0
1,1,1,-4.4,-7,-4.6,GO:0002768,immune response-regulating cell surface receptor signaling pathway,M111,3,0
1,1,1,-2.9,-2.7,-5.4,GO:0002062,chondrocyte differentiation,M111,3,0
1,1,1,-3.5,-5.2,-2.2,R-HSA-9006925,Intracellular signaling by second messengers,M111,3,0
1,1,1,-4.6,-6.7,-5.2,GO:0002366,leukocyte activation involved in immune response,M111,3,0
1,1,1,-7.5,-6.4,-4,GO:0002009,morphogenesis of an epithelium,M111,3,0
1,1,1,-10,-5.8,-3.7,GO:0048732,gland development,M111,3,0
1,1,1,-3,-5.5,-4,GO:0002285,lymphocyte activation involved in immune response,M111,3,0
1,1,1,-17,-7.5,-5.5,GO:2000628,regulation of miRNA metabolic process,M111,3,0
1,1,1,-8.5,-4.1,-4.6,GO:0001654,eye development,M111,3,0
1,1,1,-3.1,-2.4,-6.3,M7,PID FCER1 PATHWAY,M111,3,0
1,1,1,-12,-9.9,-4.7,GO:0007167,enzyme-linked receptor protein signaling pathway,M111,3,0
1,1,1,-2.5,-4.1,-2.6,R-HSA-168179,Toll Like Receptor TLR1:TLR2 Cascade,M111,3,0
1,1,1,-5.4,-3.6,-3.8,GO:0061351,neural precursor cell proliferation,M111,3,0
1,1,1,-3.9,-3.6,-4.4,GO:0046632,alpha-beta T cell differentiation,M111,3,0
1,1,1,-3.6,-7.5,-4.8,GO:0071772,response to BMP,M111,3,0
1,1,1,-2.9,-2.9,-3.5,GO:0032330,regulation of chondrocyte differentiation,M111,3,0
1,1,1,-2.8,-4.2,-5.9,R-HSA-2871796,FCERI mediated MAPK activation,M111,3,0
1,0,1,-2.1,0,-2.1,GO:0048538,thymus development,M101,2,0
1,0,1,-2.2,0,-2,M233,PID EPO PATHWAY,M101,2,0
0,1,1,0,-7.1,-2.9,GO:0045785,positive regulation of cell adhesion,M011,2,0
1,1,0,-2.5,-2.7,0,R-HSA-448424,Interleukin-17 signaling,M110,2,0
0,1,1,0,-3.4,-3.7,GO:0048812,neuron projection morphogenesis,M011,2,0
1,1,0,-2.6,-3.4,0,GO:0072012,glomerulus vasculature development,M110,2,0
1,1,0,-4.2,-2.1,0,R-HSA-450282,MAPK targets/ Nuclear events mediated by MAP kinases,M110,2,0
0,1,1,0,-3.3,-3.7,GO:0002683,negative regulation of immune system process,M011,2,0
1,0,1,-2.1,0,-2.9,GO:0048546,digestive tract morphogenesis,M101,2,0
1,0,1,-2.5,0,-2.6,M33,PID GLYPICAN 1PATHWAY,M101,2,0
1,1,0,-10,-4.4,0,GO:0071407,cellular response to organic cyclic compound,M110,2,0
1,0,1,-3.7,0,-2.9,GO:0061515,myeloid cell development,M101,2,0
1,1,0,-4.9,-2.9,0,hsa04915,Estrogen signaling pathway,M110,2,0
0,1,1,0,-3.5,-3.9,GO:0031175,neuron projection development,M011,2,0
1,0,1,-2.6,0,-2.2,GO:0032688,negative regulation of interferon-beta production,M101,2,0
1,1,0,-2.6,-2.2,0,GO:0045620,negative regulation of lymphocyte differentiation,M110,2,0
1,1,0,-2.5,-3,0,WP34,Ovarian infertility,M110,2,0
1,1,0,-5.5,-3.1,0,GO:0002262,myeloid cell homeostasis,M110,2,0
1,1,0,-4.9,-3.2,0,GO:0071277,cellular response to calcium ion,M110,2,0
1,1,0,-2.9,-2.3,0,GO:0070169,positive regulation of biomineral tissue development,M110,2,0
1,1,0,-3.5,-3.5,0,GO:0007369,gastrulation,M110,2,0
1,0,1,-2.1,0,-2.3,WP3678,Amplification and expansion of oncogenic pathways as metastatic traits,M101,2,0
1,1,0,-2.4,-3.7,0,GO:0034616,response to laminar fluid shear stress,M110,2,0
0,1,1,0,-4.8,-4.8,R-HSA-2029480,Fcgamma receptor (FCGR) dependent phagocytosis,M011,2,0
1,1,0,-4.8,-2.1,0,GO:0051961,negative regulation of nervous system development,M110,2,0
0,1,1,0,-3.3,-2.5,GO:0045087,innate immune response,M011,2,0
0,1,1,0,-4.1,-5.7,R-HSA-512988,"Interleukin-3, Interleukin-5 and GM-CSF signaling",M011,2,0
1,1,0,-2.1,-3.1,0,GO:0090183,regulation of kidney development,M110,2,0
1,1,0,-2.1,-2.8,0,GO:0043200,response to amino acid,M110,2,0
0,1,1,0,-2.9,-2.1,R-HSA-201681,TCF dependent signaling in response to WNT,M011,2,0
1,1,0,-4,-3.1,0,GO:0045669,positive regulation of osteoblast differentiation,M110,2,0
1,1,0,-2.8,-3.2,0,GO:0001947,heart looping,M110,2,0
0,1,1,0,-2,-2.2,GO:0046533,negative regulation of photoreceptor cell differentiation,M011,2,0
0,1,1,0,-2.1,-3.4,R-HSA-114604,GPVI-mediated activation cascade,M011,2,0
1,1,0,-3.6,-2.1,0,R-HSA-112043,PLC beta mediated events,M110,2,0
1,1,0,-4.8,-3.3,0,WP2853,Endoderm differentiation,M110,2,0
1,1,0,-7.1,-2.7,0,GO:0009755,hormone-mediated signaling pathway,M110,2,0
0,1,1,0,-3.6,-2.3,WP363,Wnt signaling pathway,M011,2,0
1,0,1,-6.3,0,-2.6,WP3972,PDGFR beta pathway,M101,2,0
0,1,1,0,-3.1,-2.1,GO:0090102,cochlea development,M011,2,0
1,0,1,-4.5,0,-2.2,WP4239,Epithelial to mesenchymal transition in colorectal cancer,M101,2,0
1,0,1,-3,0,-2.4,hsa05220,Chronic myeloid leukemia,M101,2,0
1,1,0,-2.3,-2.9,0,R-HSA-111885,Opioid Signalling,M110,2,0
1,0,1,-2.8,0,-2.1,WP1528,Physiological and pathological hypertrophy of the heart,M101,2,0
1,0,1,-3.6,0,-2,GO:0035116,embryonic hindlimb morphogenesis,M101,2,0
1,1,0,-2.8,-2.3,0,GO:0021781,glial cell fate commitment,M110,2,0
1,0,1,-2.8,0,-3.6,R-HSA-186763,Downstream signal transduction,M101,2,0
1,0,1,-2.4,0,-2.3,GO:0060644,mammary gland epithelial cell differentiation,M101,2,0
0,1,1,0,-4.1,-3.3,GO:0000902,cell morphogenesis,M011,2,0
1,0,1,-2.3,0,-2.4,GO:0060251,regulation of glial cell proliferation,M101,2,0
1,1,0,-3.4,-2.7,0,GO:0014706,striated muscle tissue development,M110,2,0
0,1,1,0,-3.2,-4.6,hsa04666,Fc gamma R-mediated phagocytosis,M011,2,0
1,1,0,-6,-2.2,0,GO:0021766,hippocampus development,M110,2,0
1,1,0,-6,-2.1,0,GO:0030856,regulation of epithelial cell differentiation,M110,2,0
0,1,1,0,-3.3,-2.5,R-HSA-8951430,RUNX3 regulates WNT signaling,M011,2,0
1,1,0,-2.9,-2.2,0,R-HSA-913531,Interferon Signaling,M110,2,0
0,1,1,0,-5.7,-3.7,GO:0022407,regulation of cell-cell adhesion,M011,2,0
0,1,1,0,-2.1,-5.2,R-HSA-9664417,Leishmania phagocytosis,M011,2,0
0,1,1,0,-3.2,-3.8,GO:0007411,axon guidance,M011,2,0
1,1,0,-2.7,-2.1,0,R-HSA-1912422,Pre-NOTCH Expression and Processing,M110,2,0
1,0,1,-3.5,0,-3.3,R-HSA-9679191,Potential therapeutics for SARS,M101,2,0
0,1,1,0,-2.1,-2.9,GO:0050803,regulation of synapse structure or activity,M011,2,0
1,1,0,-2.1,-3.6,0,GO:0072189,ureter development,M110,2,0
1,1,0,-3.5,-2.3,0,WP3646,Hepatitis C and hepatocellular carcinoma,M110,2,0
1,0,1,-4.1,0,-3,hsa05235,PD-L1 expression and PD-1 checkpoint pathway in cancer,M101,2,0
1,1,0,-4.7,-2.7,0,hsa05152,Tuberculosis,M110,2,0
1,1,0,-4.5,-6.3,0,GO:0035914,skeletal muscle cell differentiation,M110,2,0
0,1,1,0,-3.3,-2.1,R-HSA-1280218,Adaptive Immune System,M011,2,0
1,0,1,-4.3,0,-2.4,GO:0040013,negative regulation of locomotion,M101,2,0
0,1,1,0,-3,-2.8,GO:0032989,cellular anatomical entity morphogenesis,M011,2,0
0,1,1,0,-2.8,-2.5,GO:0032735,positive regulation of interleukin-12 production,M011,2,0
1,1,0,-2.7,-2.4,0,GO:0007565,female pregnancy,M110,2,0
1,1,0,-5.7,-2.1,0,M229,PID P38 ALPHA BETA DOWNSTREAM PATHWAY,M110,2,0
1,1,0,-2.5,-2.7,0,GO:0030101,natural killer cell activation,M110,2,0
1,0,1,-2.7,0,-3.3,WP3937,Microglia pathogen phagocytosis pathway,M101,2,0
1,1,0,-3.4,-2,0,GO:0045586,regulation of gamma-delta T cell differentiation,M110,2,0
1,1,0,-4,-2,0,GO:0021761,limbic system development,M110,2,0
0,1,1,0,-3.5,-2.5,GO:0046651,lymphocyte proliferation,M011,2,0
1,1,0,-4,-2.7,0,hsa04010,MAPK signaling pathway,M110,2,0
1,1,0,-2.5,-2.6,0,GO:0044703,multi-organism reproductive process,M110,2,0
1,1,0,-2.6,-3.8,0,GO:0071222,cellular response to lipopolysaccharide,M110,2,0
1,1,0,-2.9,-4.1,0,GO:0061440,kidney vasculature development,M110,2,0
1,1,0,-3.2,-2.2,0,GO:0045576,mast cell activation,M110,2,0
1,1,0,-3.1,-2.7,0,R-HSA-168164,Toll Like Receptor 3 (TLR3) Cascade,M110,2,0
1,0,1,-6.2,0,-2.1,GO:0072091,regulation of stem cell proliferation,M101,2,0
1,1,0,-3.1,-2,0,GO:2000648,positive regulation of stem cell proliferation,M110,2,0
1,1,0,-2.7,-2.8,0,hsa05211,Renal cell carcinoma,M110,2,0
1,1,0,-2.9,-2.8,0,GO:0045055,regulated exocytosis,M110,2,0
1,0,1,-3.2,0,-2.8,hsa04148,Efferocytosis,M101,2,0
0,1,1,0,-2.4,-2.1,GO:0048638,regulation of developmental growth,M011,2,0
0,1,1,0,-3.6,-2.3,R-HSA-1257604,PIP3 activates AKT signaling,M011,2,0
1,1,0,-2.3,-2.5,0,R-HSA-4086398,Ca2+ pathway,M110,2,0
1,0,1,-10,0,-4.9,GO:0060021,roof of mouth development,M101,2,0
1,1,0,-3.4,-2.6,0,R-HSA-76002,"Platelet activation, signaling and aggregation",M110,2,0
1,0,1,-3.5,0,-3.1,GO:0008593,regulation of Notch signaling pathway,M101,2,0
1,1,0,-2.3,-2.5,0,GO:0031641,regulation of myelination,M110,2,0
1,1,0,-2.4,-3.5,0,GO:0043281,regulation of cysteine-type endopeptidase activity involved in apoptotic process,M110,2,0
1,0,1,-2.4,0,-2.3,WP474,Endochondral ossification,M101,2,0
1,0,1,-2.1,0,-2.3,WP3611,Photodynamic therapy induced AP 1 survival signaling,M101,2,0
1,0,1,-5.2,0,-2.3,GO:0050680,negative regulation of epithelial cell proliferation,M101,2,0
1,1,0,-4.4,-4.4,0,WP4659,Gastrin signaling pathway,M110,2,0
1,1,0,-2.7,-2.6,0,GO:0002886,regulation of myeloid leukocyte mediated immunity,M110,2,0
1,0,1,-2.1,0,-2.4,WP4685,Melanoma,M101,2,0
1,1,0,-3.1,-2.6,0,GO:0001704,formation of primary germ layer,M110,2,0
1,1,0,-7,-3,0,GO:0010632,regulation of epithelial cell migration,M110,2,0
1,1,0,-5.7,-2.1,0,hsa05163,Human cytomegalovirus infection,M110,2,0
1,0,1,-2.8,0,-2,GO:0034204,lipid translocation,M101,2,0
1,0,1,-2.4,0,-2.8,WP4565,Neural crest cell migration in cancer,M101,2,0
0,1,1,0,-3,-2.6,R-HSA-9607240,FLT3 Signaling,M011,2,0
1,1,0,-3.6,-2.1,0,M100,PID SHP2 PATHWAY,M110,2,0
1,1,0,-3.6,-2.7,0,GO:0042752,regulation of circadian rhythm,M110,2,0
0,1,1,0,-5.8,-3.5,GO:0002757,immune response-activating signaling pathway,M011,2,0
1,1,0,-2.6,-3.1,0,GO:0061371,determination of heart left/right asymmetry,M110,2,0
1,0,1,-2.4,0,-3.9,WP3892,Development of pulmonary dendritic cells and macrophage subsets,M101,2,0
1,1,0,-2,-3.2,0,R-HSA-1489509,DAG and IP3 signaling,M110,2,0
1,0,1,-2.9,0,-2.2,hsa05214,Glioma,M101,2,0
1,0,1,-2.9,0,-3.3,WP3863,T cell antigen receptor TCR pathway during Staphylococcus aureus infection,M101,2,0
1,1,0,-3.1,-2.6,0,GO:0051147,regulation of muscle cell differentiation,M110,2,0
1,0,1,-2.9,0,-2.1,hsa05223,Non-small cell lung cancer,M101,2,0
1,0,1,-2.8,0,-3.7,hsa04072,Phospholipase D signaling pathway,M101,2,0
1,0,1,-5.1,0,-2.8,GO:2000146,negative regulation of cell motility,M101,2,0
0,1,1,0,-2.1,-3.3,M141,PID PI3KCI PATHWAY,M011,2,0
0,1,1,0,-3,-2.3,R-HSA-2029481,FCGR activation,M011,2,0
1,1,0,-2.2,-2.1,0,GO:0010935,regulation of macrophage cytokine production,M110,2,0
1,0,1,-3,0,-2.4,GO:0045665,negative regulation of neuron differentiation,M101,2,0
1,1,0,-2.7,-2.8,0,R-HSA-450294,MAP kinase activation,M110,2,0
1,1,0,-6,-3.8,0,WP437,EGF EGFR signaling pathway,M110,2,0
1,0,1,-3.1,0,-2.5,GO:0021987,cerebral cortex development,M101,2,0
1,1,0,-7.7,-2.8,0,WP5087,Pleural mesothelioma,M110,2,0
1,1,0,-4,-3,0,GO:0048738,cardiac muscle tissue development,M110,2,0
1,1,0,-2.1,-2.7,0,hsa04929,GnRH secretion,M110,2,0
0,1,1,0,-3,-2.3,GO:0038096,Fc-gamma receptor signaling pathway involved in phagocytosis,M011,2,0
1,1,0,-6.2,-3.1,0,WP3932,Focal adhesion PI3K Akt mTOR signaling pathway,M110,2,0
1,0,1,-4.4,0,-3.4,GO:0003170,heart valve development,M101,2,0
0,1,1,0,-3,-2.3,GO:0002433,immune response-regulating cell surface receptor signaling pathway involved in phagocytosis,M011,2,0
1,1,0,-3.8,-4.3,0,GO:0072132,mesenchyme morphogenesis,M110,2,0
1,1,0,-4.2,-2.3,0,GO:0010634,positive regulation of epithelial cell migration,M110,2,0
1,1,0,-2.4,-2.1,0,GO:0003203,endocardial cushion morphogenesis,M110,2,0
1,0,1,-5.9,0,-2.5,GO:0060348,bone development,M101,2,0
1,1,0,-2.7,-5.2,0,GO:0007519,skeletal muscle tissue development,M110,2,0
1,0,1,-2.4,0,-2.8,WP4564,Neural crest cell migration during development,M101,2,0
0,1,1,0,-2.7,-2.1,WP5224,2q37 copy number variation syndrome,M011,2,0
0,1,1,0,-2.6,-3.7,GO:0043065,positive regulation of apoptotic process,M011,2,0
0,1,1,0,-2.8,-3.5,GO:0001503,ossification,M011,2,0
1,1,0,-2.5,-2.1,0,GO:0010565,regulation of cellular ketone metabolic process,M110,2,0
1,1,0,-2,-2.3,0,R-HSA-9823730,Formation of definitive endoderm,M110,2,0
0,1,1,0,-3.2,-2.6,R-HSA-9705462,Inactivation of CSF3 (G-CSF) signaling,M011,2,0
1,1,0,-2.2,-3.3,0,R-HSA-400206,Regulation of lipid metabolism by PPARalpha,M110,2,0
1,1,0,-2.8,-2.7,0,GO:2001053,regulation of mesenchymal cell apoptotic process,M110,2,0
1,1,0,-4.6,-4.7,0,GO:0001822,kidney development,M110,2,0
1,1,0,-3.1,-2.2,0,GO:0006909,phagocytosis,M110,2,0
1,0,1,-2.4,0,-4.5,GO:0021952,central nervous system projection neuron axonogenesis,M101,2,0
1,1,0,-4,-2,0,hsa05140,Leishmaniasis,M110,2,0
1,1,0,-2.1,-4.1,0,GO:0072009,nephron epithelium development,M110,2,0
0,1,1,0,-2.9,-3.2,CORUM:2694,ERG-JUN-FOS DNA-protein complex,M011,2,0
1,1,0,-2.5,-2.1,0,GO:0032869,cellular response to insulin stimulus,M110,2,0
1,0,1,-2.3,0,-2.9,R-HSA-9013149,RAC1 GTPase cycle,M101,2,0
0,1,1,0,-2.8,-2.5,GO:0090287,regulation of cellular response to growth factor stimulus,M011,2,0
1,1,0,-2.3,-3.6,0,GO:0001101,response to acid chemical,M110,2,0
1,0,1,-4.2,0,-2.1,WP3929,Chemokine signaling pathway,M101,2,0
0,1,1,0,-2.8,-2.9,GO:0042476,odontogenesis,M011,2,0
1,1,0,-2.9,-4.1,0,GO:0061437,renal system vasculature development,M110,2,0
1,0,1,-6.5,0,-3,GO:0021988,olfactory lobe development,M101,2,0
1,1,0,-3.9,-2.9,0,GO:0030031,cell projection assembly,M110,2,0
1,1,0,-2.4,-2.5,0,M26,PID NFKAPPAB ATYPICAL PATHWAY,M110,2,0
0,1,1,0,-3.4,-2.8,GO:0009620,response to fungus,M011,2,0
1,1,0,-3.7,-3.5,0,hsa04550,Signaling pathways regulating pluripotency of stem cells,M110,2,0
0,1,1,0,-2.2,-2.1,M223,PID BETA CATENIN NUC PATHWAY,M011,2,0
1,1,0,-2.3,-2.1,0,GO:1903844,regulation of cellular response to transforming growth factor beta stimulus,M110,2,0
1,1,0,-2.7,-2,0,R-HSA-9758941,Gastrulation,M110,2,0
1,1,0,-2.6,-2,0,GO:2000977,regulation of forebrain neuron differentiation,M110,2,0
1,1,0,-2.9,-3.1,0,GO:0045621,positive regulation of lymphocyte differentiation,M110,2,0
1,1,0,-2.2,-2.2,0,R-HSA-9013148,CDC42 GTPase cycle,M110,2,0
0,1,1,0,-3.5,-2.5,GO:0032943,mononuclear cell proliferation,M011,2,0
1,0,1,-6.8,0,-2.9,hsa05221,Acute myeloid leukemia,M101,2,0
0,1,1,0,-2.1,-5.2,R-HSA-9664422,FCGR3A-mediated phagocytosis,M011,2,0
1,1,0,-4.6,-3.2,0,R-HSA-877300,Interferon gamma signaling,M110,2,0
1,1,0,-2.7,-4.9,0,GO:0120161,regulation of cold-induced thermogenesis,M110,2,0
1,1,0,-2.8,-2.9,0,GO:0009855,determination of bilateral symmetry,M110,2,0
1,1,0,-2,-2.6,0,hsa05418,Fluid shear stress and atherosclerosis,M110,2,0
1,1,0,-2.2,-2.4,0,GO:0002861,regulation of inflammatory response to antigenic stimulus,M110,2,0
1,1,0,-2,-2.3,0,GO:0042832,defense response to protozoan,M110,2,0
1,1,0,-2.7,-2,0,GO:0006887,exocytosis,M110,2,0
0,1,1,0,-2.9,-3.2,CORUM:2695,ETS2-FOS-JUN complex,M011,2,0
1,1,0,-5.9,-3.2,0,GO:0002065,columnar/cuboidal epithelial cell differentiation,M110,2,0
0,1,1,0,-2.4,-2.8,GO:0002313,mature B cell differentiation involved in immune response,M011,2,0
1,1,0,-2.8,-3.5,0,GO:0071219,cellular response to molecule of bacterial origin,M110,2,0
1,1,0,-4.1,-3.8,0,GO:0043433,negative regulation of DNA-binding transcription factor activity,M110,2,0
1,0,1,-4.5,0,-3.3,WP2203,Thymic stromal lymphopoietin TSLP signaling pathway,M101,2,0
1,1,0,-2.9,-3.2,0,GO:0060972,left/right pattern formation,M110,2,0
1,1,0,-2.6,-2.5,0,GO:0010950,positive regulation of endopeptidase activity,M110,2,0
1,1,0,-4.8,-2.7,0,GO:0046903,secretion,M110,2,0
1,1,0,-2.1,-2.4,0,GO:0045722,positive regulation of gluconeogenesis,M110,2,0
1,1,0,-2.4,-3.1,0,GO:0001656,metanephros development,M110,2,0
1,0,1,-7.1,0,-3.2,GO:0021772,olfactory bulb development,M101,2,0
1,1,0,-2.8,-2,0,GO:0035282,segmentation,M110,2,0
1,1,0,-2.9,-5.1,0,R-HSA-157118,Signaling by NOTCH,M110,2,0
1,1,0,-4.2,-5.4,0,GO:0002702,positive regulation of production of molecular mediator of immune response,M110,2,0
1,1,0,-2.8,-2.3,0,R-HSA-202427,Phosphorylation of CD3 and TCR zeta chains,M110,2,0
1,1,0,-2.2,-2.4,0,WP2795,Cardiac hypertrophic response,M110,2,0
1,1,0,-3.5,-2.5,0,GO:0035270,endocrine system development,M110,2,0
0,1,1,0,-2.1,-2.9,GO:0050807,regulation of synapse organization,M011,2,0
1,1,0,-2.1,-4.4,0,GO:0120162,positive regulation of cold-induced thermogenesis,M110,2,0
1,1,0,-2.1,-2.4,0,GO:0048341,paraxial mesoderm formation,M110,2,0
1,1,0,-3.9,-2.9,0,GO:0032940,secretion by cell,M110,2,0
0,1,1,0,-5,-4.1,GO:0050863,regulation of T cell activation,M011,2,0
1,0,1,-3.1,0,-3.5,hsa05210,Colorectal cancer,M101,2,0
0,1,1,0,-2,-2.2,GO:0021800,cerebral cortex tangential migration,M011,2,0
1,0,1,-3.6,0,-2.5,hsa04310,Wnt signaling pathway,M101,2,0
1,1,0,-7.2,-2.8,0,R-HSA-9018519,Estrogen-dependent gene expression,M110,2,0
0,1,1,0,-2,-2.5,GO:0030833,regulation of actin filament polymerization,M011,2,0
1,0,1,-2.6,0,-2.4,hsa01522,Endocrine resistance,M101,2,0
0,1,1,0,-3.2,-3.8,GO:0097485,neuron projection guidance,M011,2,0
0,1,1,0,-3.3,-2.5,GO:0002467,germinal center formation,M011,2,0
1,0,1,-4,0,-2.7,WP428,Wnt signaling,M101,2,0
1,0,1,-2.8,0,-4.2,GO:0021955,central nervous system neuron axonogenesis,M101,2,0
1,0,1,-2.6,0,-2.2,GO:0033173,calcineurin-NFAT signaling cascade,M101,2,0
1,1,0,-5.9,-2.1,0,GO:0001525,angiogenesis,M110,2,0
1,1,0,-2.1,-2.4,0,R-HSA-9022707,MECP2 regulates transcription factors,M110,2,0
1,1,0,-2.8,-3.7,0,GO:0007179,transforming growth factor beta receptor signaling pathway,M110,2,0
1,1,0,-2.7,-2,0,GO:0050777,negative regulation of immune response,M110,2,0
0,1,1,0,-4.5,-6.4,GO:0051249,regulation of lymphocyte activation,M011,2,0
0,1,1,0,-5,-2.2,GO:0038093,Fc receptor signaling pathway,M011,2,0
1,0,1,-4.6,0,-2.3,WP127,IL 5 signaling pathway,M101,2,0
1,1,0,-2.1,-2.1,0,GO:0008360,regulation of cell shape,M110,2,0
1,1,0,-3.3,-2,0,hsa05150,Staphylococcus aureus infection,M110,2,0
0,1,1,0,-2.1,-6.7,GO:0009611,response to wounding,M011,2,0
0,1,1,0,-3.7,-2,R-HSA-5663202,Diseases of signal transduction by growth factor receptors and second messengers,M011,2,0
0,1,1,0,-2.3,-2.2,R-HSA-8939236,RUNX1 regulates transcription of genes involved in differentiation of HSCs,M011,2,0
1,0,1,-2.3,0,-2.4,GO:0050764,regulation of phagocytosis,M101,2,0
1,1,0,-3.6,-4.6,0,GO:0070670,response to interleukin-4,M110,2,0
1,0,1,-3.4,0,-2.4,M99,PID TXA2PATHWAY,M101,2,0
1,0,1,-2.4,0,-3,GO:0021510,spinal cord development,M101,2,0
1,0,1,-2.4,0,-2.3,WP4808,Endochondral ossification with skeletal dysplasias,M101,2,0
1,0,1,-5,0,-3,GO:0030336,negative regulation of cell migration,M101,2,0
1,0,1,-3.9,0,-2.3,hsa04062,Chemokine signaling pathway,M101,2,0
1,0,1,-4,0,-2.1,GO:1905314,semi-lunar valve development,M101,2,0
1,0,1,-2.4,0,-2.5,GO:0060441,epithelial tube branching involved in lung morphogenesis,M101,2,0
1,0,1,-3.4,0,-2.6,WP4217,Ebola virus infection in host,M101,2,0
0,1,1,0,-2.8,-2.7,WP4823,Genes controlling nephrogenesis,M011,2,0
1,1,0,-5,-3.4,0,GO:0051592,response to calcium ion,M110,2,0
1,0,1,-3,0,-2.7,GO:0045577,regulation of B cell differentiation,M101,2,0
1,1,0,-2.8,-2.3,0,GO:0048339,paraxial mesoderm development,M110,2,0
1,0,1,-3.6,0,-5.2,hsa04664,Fc epsilon RI signaling pathway,M101,2,0
0,1,1,0,-2.2,-2.5,GO:1990858,cellular response to lectin,M011,2,0
1,0,1,-3,0,-2.4,GO:0030500,regulation of bone mineralization,M101,2,0
1,0,1,-2.1,0,-2.1,GO:0022602,ovulation cycle process,M101,2,0
1,1,0,-3.3,-2.7,0,WP2873,Aryl hydrocarbon receptor pathway,M110,2,0
1,1,0,-3.5,-2,0,GO:0019827,stem cell population maintenance,M110,2,0
1,0,1,-4,0,-2.4,R-HSA-1912408,Pre-NOTCH Transcription and Translation,M101,2,0
1,0,1,-2.1,0,-2.4,GO:0043491,phosphatidylinositol 3-kinase/protein kinase B signal transduction,M101,2,0
1,0,1,-4,0,-2.1,hsa04912,GnRH signaling pathway,M101,2,0
1,1,0,-2.5,-3.8,0,R-HSA-9664433,Leishmania parasite growth and survival,M110,2,0
1,1,0,-2.9,-2.5,0,GO:0043534,blood vessel endothelial cell migration,M110,2,0
1,1,0,-2.9,-4,0,hsa05323,Rheumatoid arthritis,M110,2,0
0,1,1,0,-2.7,-2.1,GO:0042092,type 2 immune response,M011,2,0
1,0,1,-3.1,0,-2.3,GO:0045646,regulation of erythrocyte differentiation,M101,2,0
1,1,0,-3,-3.1,0,GO:0060326,cell chemotaxis,M110,2,0
1,1,0,-2.7,-2.1,0,GO:0050871,positive regulation of B cell activation,M110,2,0
0,1,1,0,-3.6,-2.3,GO:0032332,positive regulation of chondrocyte differentiation,M011,2,0
1,1,0,-5.4,-5,0,GO:0072001,renal system development,M110,2,0
1,1,0,-7.5,-2.9,0,GO:0010594,regulation of endothelial cell migration,M110,2,0
1,1,0,-4.4,-2.1,0,GO:0060828,regulation of canonical Wnt signaling pathway,M110,2,0
1,0,1,-3.2,0,-2.1,GO:0045332,phospholipid translocation,M101,2,0
1,1,0,-7.6,-5.2,0,hsa05321,Inflammatory bowel disease,M110,2,0
1,0,1,-6.7,0,-6.7,GO:0048706,embryonic skeletal system development,M101,2,0
1,0,1,-3.6,0,-2.7,GO:0003179,heart valve morphogenesis,M101,2,0
1,0,1,-3.8,0,-2.1,GO:0060760,positive regulation of response to cytokine stimulus,M101,2,0
1,1,0,-2.3,-2.3,0,GO:1901796,regulation of signal transduction by p53 class mediator,M110,2,0
0,1,1,0,-5.5,-2.1,GO:1901652,response to peptide,M011,2,0
1,0,1,-2.3,0,-2.3,GO:0030888,regulation of B cell proliferation,M101,2,0
1,0,1,-2.9,0,-5.1,hsa04660,T cell receptor signaling pathway,M101,2,0
1,1,0,-2.4,-2.9,0,GO:2000738,positive regulation of stem cell differentiation,M110,2,0
1,1,0,-4.5,-3.1,0,GO:0071375,cellular response to peptide hormone stimulus,M110,2,0
1,0,1,-3.7,0,-2,WP4255,Non small cell lung cancer,M101,2,0
1,1,0,-3.6,-2.3,0,GO:0021545,cranial nerve development,M110,2,0
1,1,0,-3.5,-2,0,GO:0035904,aorta development,M110,2,0
1,0,1,-2.6,0,-2.4,GO:0050869,negative regulation of B cell activation,M101,2,0
0,1,1,0,-3.6,-3.6,GO:0048858,cell projection morphogenesis,M011,2,0
1,1,0,-3,-4.6,0,GO:0002703,regulation of leukocyte mediated immunity,M110,2,0
1,1,0,-2.7,-4.3,0,GO:0060395,SMAD protein signal transduction,M110,2,0
1,1,0,-2.5,-2.7,0,GO:0032890,regulation of organic acid transport,M110,2,0
1,1,0,-2.1,-2.4,0,WP3299,let 7 inhibition of ES cell reprogramming,M110,2,0
1,1,0,-3.3,-2.7,0,R-HSA-112040,G-protein mediated events,M110,2,0
1,1,0,-8.3,-2.8,0,GO:0030522,intracellular receptor signaling pathway,M110,2,0
1,1,0,-4.4,-2.1,0,hsa04350,TGF-beta signaling pathway,M110,2,0
1,1,0,-3.2,-2.8,0,GO:0048340,paraxial mesoderm morphogenesis,M110,2,0
0,1,1,0,-2.4,-2.6,GO:0061760,antifungal innate immune response,M011,2,0
0,1,1,0,-4.2,-7.3,R-HSA-912631,Regulation of signaling by CBL,M011,2,0
1,1,0,-12,-5.5,0,GO:0006351,DNA-templated transcription,M110,2,0
1,0,1,-2.1,0,-2.1,GO:0060412,ventricular septum morphogenesis,M101,2,0
1,0,1,-2.1,0,-4.2,GO:0060363,cranial suture morphogenesis,M101,2,0
0,1,1,0,-2,-2.2,GO:0046532,regulation of photoreceptor cell differentiation,M011,2,0
1,1,0,-4.1,-4.2,0,GO:0002699,positive regulation of immune effector process,M110,2,0
0,1,1,0,-2.3,-2.7,GO:0002312,B cell activation involved in immune response,M011,2,0
1,0,1,-5,0,-6.4,GO:0048704,embryonic skeletal system morphogenesis,M101,2,0
1,1,0,-3.1,-3.4,0,WP1541,Energy metabolism,M110,2,0
0,1,1,0,-2,-2.2,R-HSA-937039,IRAK1 recruits IKK complex,M011,2,0
0,1,1,0,-3.4,-3.4,GO:0007409,axonogenesis,M011,2,0
0,1,1,0,-5.7,-6.2,GO:0006954,inflammatory response,M011,2,0
1,1,0,-2.7,-2.1,0,GO:0030501,positive regulation of bone mineralization,M110,2,0
1,0,1,-6.1,0,-2.6,hsa04218,Cellular senescence,M101,2,0
1,0,1,-4.2,0,-3.8,GO:0050864,regulation of B cell activation,M101,2,0
1,1,0,-3.2,-2.9,0,GO:0051098,regulation of binding,M110,2,0
1,1,0,-2.4,-2.1,0,M270,PID MAPK TRK PATHWAY,M110,2,0
0,1,1,0,-3,-2.2,GO:0070661,leukocyte proliferation,M011,2,0
1,1,0,-2.8,-3.1,0,GO:0043280,positive regulation of cysteine-type endopeptidase activity involved in apoptotic process,M110,2,0
1,1,0,-3.6,-3.6,0,GO:0043254,regulation of protein-containing complex assembly,M110,2,0
1,1,0,-2.8,-3.6,0,GO:0031016,pancreas development,M110,2,0
1,1,0,-3.2,-2.8,0,R-HSA-5607763,CLEC7A (Dectin-1) induces NFAT activation,M110,2,0
1,1,0,-3.4,-3.2,0,R-HSA-166166,MyD88-independent TLR4 cascade,M110,2,0
1,1,0,-2.2,-2.8,0,GO:0045581,negative regulation of T cell differentiation,M110,2,0
0,1,1,0,-2.2,-2.5,GO:1990840,response to lectin,M011,2,0
1,1,0,-2.6,-3.5,0,R-HSA-975138,TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation,M110,2,0
0,1,1,0,-3.7,-2.8,R-HSA-4411364,Binding of TCF/LEF:CTNNB1 to target gene promoters,M011,2,0
0,1,1,0,-2.2,-2.6,R-HSA-9680350,Signaling by CSF1 (M-CSF) in myeloid cells,M011,2,0
1,1,0,-2.6,-2.8,0,WP4336,ncRNAs involved in Wnt signaling in hepatocellular carcinoma,M110,2,0
0,1,1,0,-2.9,-3.4,R-HSA-9674555,Signaling by CSF3 (G-CSF),M011,2,0
1,1,0,-3.4,-2.1,0,GO:0045137,development of primary sexual characteristics,M110,2,0
0,1,1,0,-2,-2.2,CORUM:1372,Rb-tal-1-E2A-Lmo2-Ldb1 complex,M011,2,0
0,1,1,0,-4.8,-2,GO:0032496,response to lipopolysaccharide,M011,2,0
1,1,0,-2.2,-2.6,0,GO:0043502,regulation of muscle adaptation,M110,2,0
1,1,0,-6.3,-2.4,0,R-HSA-8939211,ESR-mediated signaling,M110,2,0
1,1,0,-2.9,-2.2,0,WP4141,PI3K AKT mTOR vitamin D3 signaling,M110,2,0
0,1,1,0,-4.1,-2.8,GO:0042088,T-helper 1 type immune response,M011,2,0
1,1,0,-3.2,-3.1,0,GO:0019932,second-messenger-mediated signaling,M110,2,0
1,1,0,-3.1,-3.3,0,GO:0007368,determination of left/right symmetry,M110,2,0
1,1,0,-3.4,-3.2,0,R-HSA-937061,TRIF(TICAM1)-mediated TLR4 signaling,M110,2,0
1,1,0,-2.6,-5,0,GO:0051145,smooth muscle cell differentiation,M110,2,0
1,1,0,-2.4,-2.8,0,GO:0031341,regulation of cell killing,M110,2,0
0,1,1,0,-4,-2.2,GO:0046634,regulation of alpha-beta T cell activation,M011,2,0
0,1,1,0,-3.1,-2.3,GO:0051345,positive regulation of hydrolase activity,M011,2,0
1,1,0,-4.8,-2.5,0,GO:0043255,regulation of carbohydrate biosynthetic process,M110,2,0
0,1,1,0,-4.4,-2.8,GO:0032655,regulation of interleukin-12 production,M011,2,0
1,1,0,-2.8,-2.9,0,GO:0009799,specification of symmetry,M110,2,0
1,1,0,-4.3,-5.3,0,R-HSA-381340,Transcriptional regulation of white adipocyte differentiation,M110,2,0
1,1,0,-2.8,-2.3,0,R-HSA-525793,Myogenesis,M110,2,0
0,1,1,0,-4.9,-3.5,GO:0002253,activation of immune response,M011,2,0
1,1,0,-2.1,-2.4,0,GO:0032763,regulation of mast cell cytokine production,M110,2,0
1,1,0,-2.6,-2,0,WP4928,MAPK pathway in congenital thyroid cancer,M110,2,0
0,1,1,0,-2.1,-5.2,R-HSA-9664407,Parasite infection,M011,2,0
1,0,1,-3.7,0,-2.5,GO:0033077,T cell differentiation in thymus,M101,2,0
1,1,0,-5.2,-2.1,0,WP3888,VEGFA VEGFR2 signaling,M110,2,0
1,0,1,-3.3,0,-4,WP2018,RANKL RANK signaling pathway,M101,2,0
1,1,0,-2.3,-2.4,0,GO:1903707,negative regulation of hemopoiesis,M110,2,0
1,0,1,-3.7,0,-2.3,GO:0045058,T cell selection,M101,2,0
1,1,0,-4,-3.2,0,GO:0060041,retina development in camera-type eye,M110,2,0
1,1,0,-2.2,-3.2,0,GO:0002828,regulation of type 2 immune response,M110,2,0
1,1,0,-7.8,-5.3,0,GO:0051090,regulation of DNA-binding transcription factor activity,M110,2,0
1,1,0,-4.4,-2.3,0,GO:0035272,exocrine system development,M110,2,0
1,1,0,-5.6,-2.6,0,GO:0043401,steroid hormone mediated signaling pathway,M110,2,0
1,1,0,-4.5,-2.2,0,GO:0030323,respiratory tube development,M110,2,0
1,1,0,-2.6,-2.7,0,GO:0001945,lymph vessel development,M110,2,0
1,1,0,-4.3,-2.2,0,hsa05203,Viral carcinogenesis,M110,2,0
1,1,0,-4,-2.5,0,hsa04390,Hippo signaling pathway,M110,2,0
0,1,1,0,-2.4,-2.6,R-HSA-5621480,Dectin-2 family,M011,2,0
1,0,1,-6.3,0,-4.7,GO:0021544,subpallium development,M101,2,0
1,0,1,-3.7,0,-2.6,hsa05225,Hepatocellular carcinoma,M101,2,0
0,1,1,0,-3,-2.3,GO:0050832,defense response to fungus,M011,2,0
1,1,0,-4.1,-3.6,0,R-HSA-9707616,Heme signaling,M110,2,0
1,1,0,-2.9,-2.3,0,GO:0030510,regulation of BMP signaling pathway,M110,2,0
1,1,0,-3.5,-5.2,0,GO:0002718,regulation of cytokine production involved in immune response,M110,2,0
1,1,0,-2.8,-5,0,GO:0002720,positive regulation of cytokine production involved in immune response,M110,2,0
1,1,0,-2.3,-3.6,0,GO:0071229,cellular response to acid chemical,M110,2,0
0,1,1,0,-4.1,-3.3,GO:0002763,positive regulation of myeloid leukocyte differentiation,M011,2,0
1,1,0,-2.8,-2.4,0,GO:0048332,mesoderm morphogenesis,M110,2,0
0,1,1,0,-3.9,-3.1,R-HSA-5607764,CLEC7A (Dectin-1) signaling,M011,2,0
1,1,0,-4,-4.3,0,GO:0072006,nephron development,M110,2,0
0,1,1,0,-2.3,-2.7,R-HSA-8941326,RUNX2 regulates bone development,M011,2,0
1,1,0,-3.7,-5.4,0,GO:0002700,regulation of production of molecular mediator of immune response,M110,2,0
1,1,0,-2.1,-2,0,hsa04724,Glutamatergic synapse,M110,2,0
1,1,0,-3.4,-4.1,0,GO:0050890,cognition,M110,2,0
1,1,0,-2.7,-5.5,0,GO:0060538,skeletal muscle organ development,M110,2,0
1,0,1,-2.5,0,-3,WP75,Toll like receptor signaling pathway,M101,2,0
1,0,1,-2.6,0,-2.2,GO:0034635,glutathione transport,M101,2,0
1,1,0,-4.2,-4.2,0,WP5417,Cell lineage map for neuronal differentiation,M110,2,0
0,1,1,0,-3.3,-2.2,GO:0002576,platelet degranulation,M011,2,0
1,1,0,-5.3,-5,0,WP4211,Transcriptional cascade regulating adipogenesis,M110,2,0
1,1,0,-2.4,-2.1,0,GO:0001562,response to protozoan,M110,2,0
1,1,0,-5,-5.8,0,WP2355,Corticotropin releasing hormone signaling pathway,M110,2,0
0,1,1,0,-2,-2.2,R-HSA-975144,IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation,M011,2,0
1,1,0,-3,-4.1,0,GO:0002064,epithelial cell development,M110,2,0
1,1,0,-2.5,-3.8,0,R-HSA-9662851,Anti-inflammatory response favouring Leishmania parasite infection,M110,2,0
1,1,0,-2.3,-2.1,0,GO:0010952,positive regulation of peptidase activity,M110,2,0
1,1,0,-2.5,-2,0,GO:0001707,mesoderm formation,M110,2,0
1,1,0,-2.2,-2.1,0,hsa05320,Autoimmune thyroid disease,M110,2,0
1,1,0,-3.2,-3.9,0,GO:0071353,cellular response to interleukin-4,M110,2,0
1,1,0,-4.3,-2.9,0,GO:0032835,glomerulus development,M110,2,0
1,1,0,-2.1,-2.7,0,GO:0034405,response to fluid shear stress,M110,2,0
0,1,1,0,-3,-4.2,GO:0043068,positive regulation of programmed cell death,M011,2,0
1,0,1,-2.6,0,-2.2,GO:0006991,response to sterol depletion,M101,2,0
1,1,0,-4.1,-2.2,0,GO:1903555,regulation of tumor necrosis factor superfamily cytokine production,M110,2,0
0,1,1,0,-3.5,-2.1,GO:0046545,development of primary female sexual characteristics,M011,2,0
1,1,0,-3.8,-3.2,0,GO:1901653,cellular response to peptide,M110,2,0
0,1,1,0,-4.5,-2,R-HSA-3769402,Deactivation of the beta-catenin transactivating complex,M011,2,0
0,1,1,0,-4.7,-2.1,GO:0002237,response to molecule of bacterial origin,M011,2,0
1,1,0,-2.9,-2.7,0,GO:0003197,endocardial cushion development,M110,2,0
1,1,0,-2.4,-2.5,0,WP4842,Mammalian disorder of sexual development,M110,2,0
1,1,0,-3.8,-2.9,0,GO:0035051,cardiocyte differentiation,M110,2,0
1,1,0,-2.2,-3.2,0,GO:0071674,mononuclear cell migration,M110,2,0
1,1,0,-4.4,-3.6,0,GO:0002067,glandular epithelial cell differentiation,M110,2,0
1,1,0,-3.7,-2.5,0,GO:0007611,learning or memory,M110,2,0
0,1,1,0,-3.7,-3.6,GO:0120039,plasma membrane bounded cell projection morphogenesis,M011,2,0
1,1,0,-4.4,-2.5,0,GO:1901342,regulation of vasculature development,M110,2,0
0,1,1,0,-3,-3.1,GO:0061564,axon development,M011,2,0
1,1,0,-2.9,-2.5,0,GO:2001056,positive regulation of cysteine-type endopeptidase activity,M110,2,0
0,1,1,0,-2.2,-3.5,GO:0002335,mature B cell differentiation,M011,2,0
1,0,1,-3,0,-2.1,GO:0070167,regulation of biomineral tissue development,M101,2,0
0,1,1,0,-4.7,-2.2,GO:0050868,negative regulation of T cell activation,M011,2,0
0,1,1,0,-2.2,-2.5,GO:0002223,stimulatory C-type lectin receptor signaling pathway,M011,2,0
1,1,0,-3.4,-2.3,0,GO:0051897,positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction,M110,2,0
0,1,1,0,-2,-2.2,GO:1905563,negative regulation of vascular endothelial cell proliferation,M011,2,0
0,1,1,0,-4.9,-2.4,GO:0002460,adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains,M011,2,0
1,0,1,-2.3,0,-2.2,WP673,ErbB signaling pathway,M101,2,0
0,1,1,0,-3.9,-2.5,GO:0038094,Fc-gamma receptor signaling pathway,M011,2,0
1,1,0,-3.6,-2.9,0,GO:0120031,plasma membrane bounded cell projection assembly,M110,2,0
1,1,0,-12,-5.4,0,GO:0032774,RNA biosynthetic process,M110,2,0
1,1,0,-4.4,-2.1,0,GO:0010595,positive regulation of endothelial cell migration,M110,2,0
0,1,1,0,-6.4,-3,GO:0009617,response to bacterium,M011,2,0
1,0,1,-3.2,0,-2.1,M1315,SIG PIP3 SIGNALING IN B LYMPHOCYTES,M101,2,0
0,1,1,0,-2.9,-3.2,CORUM:2693,NFAT-JUN-FOS DNA-protein complex,M011,2,0
0,1,1,0,-2,-3.6,R-HSA-2730905,Role of LAT2/NTAL/LAB on calcium mobilization,M011,2,0
1,0,1,-2.8,0,-2.1,R-HSA-2032785,YAP1- and WWTR1 (TAZ)-stimulated gene expression,M101,2,0
1,0,1,-3,0,-2.8,hsa05206,MicroRNAs in cancer,M101,2,0
0,1,1,0,-2.8,-2.5,GO:0032733,positive regulation of interleukin-10 production,M011,2,0
1,1,0,-6,-3.2,0,R-HSA-109582,Hemostasis,M110,2,0
1,1,0,-2.9,-2.2,0,GO:0007406,negative regulation of neuroblast proliferation,M110,2,0
1,1,0,-2.9,-2.9,0,GO:0030857,negative regulation of epithelial cell differentiation,M110,2,0
1,0,1,-6.4,0,-2.8,WP5293,Acute myeloid leukemia,M101,2,0
1,1,0,-2.4,-2,0,GO:0097152,mesenchymal cell apoptotic process,M110,2,0
1,1,0,-2.7,-2.3,0,WP710,DNA damage response only ATM dependent,M110,2,0
1,1,0,-2.5,-3,0,GO:0019933,cAMP-mediated signaling,M110,2,0
1,0,1,-2.3,0,-3.6,WP4216,Chromosomal and microsatellite instability in colorectal cancer,M101,2,0
1,0,1,-3.3,0,-2.5,GO:0048593,camera-type eye morphogenesis,M101,2,0
0,1,1,0,-4.4,-4.3,GO:0048667,cell morphogenesis involved in neuron differentiation,M011,2,0
1,0,1,-2.7,0,-2.2,GO:2000377,regulation of reactive oxygen species metabolic process,M101,2,0
1,1,0,-2.5,-2,0,GO:0043300,regulation of leukocyte degranulation,M110,2,0
1,1,0,-2.9,-2.1,0,WP2817,Mammary gland development pathway Pregnancy and lactation Stage 3 of 4,M110,2,0
0,1,1,0,-2.6,-2.1,WP4205,MET in type 1 papillary renal cell carcinoma,M011,2,0
1,1,0,-7.8,-3.1,0,WP289,Myometrial relaxation and contraction pathways,M110,2,0
1,1,0,-3.1,-6.5,0,GO:0050679,positive regulation of epithelial cell proliferation,M110,2,0
0,1,0,0,-2.5,0,GO:0045672,positive regulation of osteoclast differentiation,M010,1,0
0,1,0,0,-2.5,0,GO:1901861,regulation of muscle tissue development,M010,1,0
1,0,0,-2.4,0,0,GO:0000271,polysaccharide biosynthetic process,M100,1,0
1,0,0,-2.1,0,0,GO:0030210,heparin biosynthetic process,M100,1,0
0,1,0,0,-2.2,0,GO:0070372,regulation of ERK1 and ERK2 cascade,M010,1,0
1,0,0,-2.7,0,0,M92,PID ANGIOPOIETIN RECEPTOR PATHWAY,M100,1,0
1,0,0,-3.2,0,0,GO:0045990,carbon catabolite regulation of transcription,M100,1,0
1,0,0,-4.5,0,0,GO:0045912,negative regulation of carbohydrate metabolic process,M100,1,0
0,1,0,0,-3.4,0,R-HSA-8939902,Regulation of RUNX2 expression and activity,M010,1,0
1,0,0,-2.4,0,0,WP53,ID signaling pathway,M100,1,0
1,0,0,-2.6,0,0,hsa04922,Glucagon signaling pathway,M100,1,0
1,0,0,-2.2,0,0,GO:0017157,regulation of exocytosis,M100,1,0
0,0,1,0,0,-3.2,R-HSA-418886,Netrin mediated repulsion signals,M001,1,0
0,1,0,0,-2.1,0,GO:0072210,metanephric nephron development,M010,1,0
0,1,0,0,-2.8,0,M190,PID TCR JNK PATHWAY,M010,1,0
1,0,0,-3.1,0,0,GO:0035909,aorta morphogenesis,M100,1,0
1,0,0,-2.4,0,0,R-HSA-5617472,Activation of anterior HOX genes in hindbrain development during early embryogenesis,M100,1,0
1,0,0,-2.4,0,0,hsa05012,Parkinson disease,M100,1,0
1,0,0,-2.1,0,0,WP3655,Hypothetical craniofacial development pathway,M100,1,0
0,1,0,0,-2,0,GO:0086026,atrial cardiac muscle cell to AV node cell signaling,M010,1,0
0,1,0,0,-2.5,0,R-HSA-1296072,Voltage gated Potassium channels,M010,1,0
0,1,0,0,-3.2,0,GO:0051146,striated muscle cell differentiation,M010,1,0
1,0,0,-2.4,0,0,GO:0021780,glial cell fate specification,M100,1,0
0,1,0,0,-3.9,0,GO:0045668,negative regulation of osteoblast differentiation,M010,1,0
1,0,0,-2.8,0,0,WP3658,Wnt beta catenin signaling pathway in leukemia,M100,1,0
1,0,0,-2.2,0,0,GO:0009791,post-embryonic development,M100,1,0
1,0,0,-2.5,0,0,GO:0046456,icosanoid biosynthetic process,M100,1,0
0,1,0,0,-2,0,WP2814,Mammary gland development pathway Puberty Stage 2 of 4,M010,1,0
0,1,0,0,-2,0,WP5381,Smith Magenis and Potocki Lupski syndrome copy number variation,M010,1,0
1,0,0,-2.9,0,0,M268,PID S1P S1P2 PATHWAY,M100,1,0
1,0,0,-3.3,0,0,GO:0002478,antigen processing and presentation of exogenous peptide antigen,M100,1,0
0,0,1,0,0,-2.5,GO:0060074,synapse maturation,M001,1,0
1,0,0,-2.3,0,0,GO:0008344,adult locomotory behavior,M100,1,0
0,1,0,0,-2.6,0,GO:1902106,negative regulation of leukocyte differentiation,M010,1,0
1,0,0,-2.2,0,0,GO:0061045,negative regulation of wound healing,M100,1,0
1,0,0,-2.1,0,0,GO:0071501,cellular response to sterol depletion,M100,1,0
1,0,0,-2,0,0,GO:0002708,positive regulation of lymphocyte mediated immunity,M100,1,0
0,1,0,0,-2.1,0,GO:0002053,positive regulation of mesenchymal cell proliferation,M010,1,0
1,0,0,-2.7,0,0,WP5180,DYRK1A involvement regarding cell proliferation in brain development,M100,1,0
0,1,0,0,-3.3,0,GO:0072080,nephron tubule development,M010,1,0
0,1,0,0,-2.1,0,GO:0071869,response to catecholamine,M010,1,0
1,0,0,-2.3,0,0,WP5322,CKAP4 signaling pathway map,M100,1,0
0,1,0,0,-2.6,0,GO:0045429,positive regulation of nitric oxide biosynthetic process,M010,1,0
1,0,0,-2.8,0,0,GO:2000191,regulation of fatty acid transport,M100,1,0
0,0,1,0,0,-2.3,GO:0030166,proteoglycan biosynthetic process,M001,1,0
0,1,0,0,-2.2,0,GO:0018108,peptidyl-tyrosine phosphorylation,M010,1,0
1,0,0,-2,0,0,GO:0046427,positive regulation of receptor signaling pathway via JAK-STAT,M100,1,0
1,0,0,-2.5,0,0,GO:0010660,regulation of muscle cell apoptotic process,M100,1,0
1,0,0,-2.8,0,0,GO:2000737,negative regulation of stem cell differentiation,M100,1,0
0,1,0,0,-2.1,0,GO:0031344,regulation of cell projection organization,M010,1,0
1,0,0,-5.6,0,0,GO:0010596,negative regulation of endothelial cell migration,M100,1,0
0,0,1,0,0,-2.3,M275,PID ALPHA SYNUCLEIN PATHWAY,M001,1,0
0,0,1,0,0,-2,GO:0002220,innate immune response activating cell surface receptor signaling pathway,M001,1,0
1,0,0,-2.1,0,0,M138,PID THROMBIN PAR4 PATHWAY,M100,1,0
0,0,1,0,0,-2.4,GO:0021515,cell differentiation in spinal cord,M001,1,0
1,0,0,-2.1,0,0,GO:1900180,regulation of protein localization to nucleus,M100,1,0
0,1,0,0,-2,0,GO:0032808,lacrimal gland development,M010,1,0
0,1,0,0,-2.6,0,GO:0061333,renal tubule morphogenesis,M010,1,0
0,1,0,0,-2.1,0,GO:0032755,positive regulation of interleukin-6 production,M010,1,0
0,1,0,0,-3.2,0,WP481,Insulin signaling,M010,1,0
0,1,0,0,-2,0,GO:0002711,positive regulation of T cell mediated immunity,M010,1,0
0,0,1,0,0,-2.6,R-HSA-428543,Inactivation of CDC42 and RAC1,M001,1,0
1,0,0,-2.1,0,0,GO:0060978,angiogenesis involved in coronary vascular morphogenesis,M100,1,0
1,0,0,-2.2,0,0,R-HSA-983231,Factors involved in megakaryocyte development and platelet production,M100,1,0
0,0,1,0,0,-2.1,WP3845,Canonical and non canonical Notch signaling,M001,1,0
0,1,0,0,-2.4,0,GO:0097531,mast cell migration,M010,1,0
1,0,0,-2.7,0,0,GO:0043405,regulation of MAP kinase activity,M100,1,0
0,1,0,0,-4.5,0,R-HSA-2559585,Oncogene Induced Senescence,M010,1,0
1,0,0,-2.6,0,0,GO:0043368,positive T cell selection,M100,1,0
0,1,0,0,-4,0,GO:0001818,negative regulation of cytokine production,M010,1,0
1,0,0,-2.8,0,0,WP1539,Angiogenesis,M100,1,0
0,1,0,0,-3.4,0,R-HSA-1989781,PPARA activates gene expression,M010,1,0
0,1,0,0,-2.2,0,GO:0007159,leukocyte cell-cell adhesion,M010,1,0
0,1,0,0,-2.3,0,GO:0060271,cilium assembly,M010,1,0
1,0,0,-2.2,0,0,hsa05030,Cocaine addiction,M100,1,0
1,0,0,-3.3,0,0,GO:0031076,embryonic camera-type eye development,M100,1,0
1,0,0,-2,0,0,GO:1903828,negative regulation of protein localization,M100,1,0
1,0,0,-2.8,0,0,GO:0060603,mammary gland duct morphogenesis,M100,1,0
0,0,1,0,0,-3.6,WP3,Transcriptional activation by NRF2 in response to phytochemicals,M001,1,0
1,0,0,-2.4,0,0,GO:0120033,negative regulation of plasma membrane bounded cell projection assembly,M100,1,0
1,0,0,-2.3,0,0,WP2380,Brain derived neurotrophic factor BDNF signaling pathway,M100,1,0
1,0,0,-4,0,0,GO:0043523,regulation of neuron apoptotic process,M100,1,0
1,0,0,-3.8,0,0,GO:0060324,face development,M100,1,0
1,0,0,-2.8,0,0,WP299,Nuclear receptors in lipid metabolism and toxicity,M100,1,0
1,0,0,-2.2,0,0,GO:0016331,morphogenesis of embryonic epithelium,M100,1,0
1,0,0,-2.4,0,0,R-HSA-9671555,Signaling by PDGFR in disease,M100,1,0
0,1,0,0,-2.2,0,WP1425,Bone morphogenic protein signaling and regulation,M010,1,0
0,1,0,0,-3.4,0,GO:0043371,"negative regulation of CD4-positive, alpha-beta T cell differentiation",M010,1,0
0,1,0,0,-2,0,R-HSA-1358803,Downregulation of ERBB2:ERBB3 signaling,M010,1,0
1,0,0,-2.3,0,0,GO:0046661,male sex differentiation,M100,1,0
1,0,0,-2.2,0,0,GO:0036294,cellular response to decreased oxygen levels,M100,1,0
1,0,0,-3.3,0,0,GO:0062013,positive regulation of small molecule metabolic process,M100,1,0
1,0,0,-3.2,0,0,GO:2000647,negative regulation of stem cell proliferation,M100,1,0
1,0,0,-3.4,0,0,GO:0045061,thymic T cell selection,M100,1,0
1,0,0,-4.4,0,0,GO:0001961,positive regulation of cytokine-mediated signaling pathway,M100,1,0
0,1,0,0,-2.1,0,R-HSA-388841,Costimulation by the CD28 family,M010,1,0
1,0,0,-2.8,0,0,GO:0033003,regulation of mast cell activation,M100,1,0
0,1,0,0,-2.3,0,GO:0052548,regulation of endopeptidase activity,M010,1,0
0,1,0,0,-2.2,0,hsa05170,Human immunodeficiency virus 1 infection,M010,1,0
1,0,0,-2.2,0,0,GO:0006911,"phagocytosis, engulfment",M100,1,0
0,1,0,0,-2.4,0,GO:0007268,chemical synaptic transmission,M010,1,0
1,0,0,-2.6,0,0,WP4269,Ethanol metabolism production of ROS by CYP2E1,M100,1,0
1,0,0,-3.8,0,0,hsa04612,Antigen processing and presentation,M100,1,0
0,1,0,0,-2.7,0,GO:0045428,regulation of nitric oxide biosynthetic process,M010,1,0
1,0,0,-2.1,0,0,R-HSA-1592230,Mitochondrial biogenesis,M100,1,0
1,0,0,-2.5,0,0,R-HSA-5362517,Signaling by Retinoic Acid,M100,1,0
1,0,0,-2.8,0,0,WP4941,GPR143 in melanocytes and retinal pigment epithelium cells,M100,1,0
1,0,0,-2.4,0,0,GO:1904031,positive regulation of cyclin-dependent protein kinase activity,M100,1,0
1,0,0,-2.1,0,0,GO:0035264,multicellular organism growth,M100,1,0
0,1,0,0,-2.2,0,GO:0071868,cellular response to monoamine stimulus,M010,1,0
0,1,0,0,-2.2,0,GO:0045064,T-helper 2 cell differentiation,M010,1,0
0,1,0,0,-2.5,0,GO:0070665,positive regulation of leukocyte proliferation,M010,1,0
1,0,0,-3.5,0,0,GO:0071248,cellular response to metal ion,M100,1,0
0,1,0,0,-4.9,0,GO:0043370,"regulation of CD4-positive, alpha-beta T cell differentiation",M010,1,0
0,1,0,0,-2.9,0,GO:0010562,positive regulation of phosphorus metabolic process,M010,1,0
1,0,0,-2.9,0,0,GO:0007595,lactation,M100,1,0
1,0,0,-2.3,0,0,R-HSA-9012852,Signaling by NOTCH3,M100,1,0
1,0,0,-3.2,0,0,hsa04216,Ferroptosis,M100,1,0
1,0,0,-2,0,0,GO:0060512,prostate gland morphogenesis,M100,1,0
1,0,0,-3.2,0,0,GO:0042594,response to starvation,M100,1,0
0,1,0,0,-2.4,0,GO:0071880,adenylate cyclase-activating adrenergic receptor signaling pathway,M010,1,0
0,0,1,0,0,-2.5,R-HSA-196807,Nicotinate metabolism,M001,1,0
1,0,0,-2.2,0,0,GO:1903670,regulation of sprouting angiogenesis,M100,1,0
1,0,0,-2.2,0,0,GO:0003229,ventricular cardiac muscle tissue development,M100,1,0
1,0,0,-3.7,0,0,WP5358,JAK STAT signaling in the regulation of Beta cells,M100,1,0
1,0,0,-3.4,0,0,GO:0001937,negative regulation of endothelial cell proliferation,M100,1,0
0,1,0,0,-3.7,0,R-HSA-5218921,VEGFR2 mediated cell proliferation,M010,1,0
1,0,0,-4.4,0,0,GO:2000736,regulation of stem cell differentiation,M100,1,0
0,1,0,0,-2.8,0,GO:0061036,positive regulation of cartilage development,M010,1,0
0,1,0,0,-2.7,0,GO:0051046,regulation of secretion,M010,1,0
1,0,0,-2.5,0,0,GO:0002639,positive regulation of immunoglobulin production,M100,1,0
1,0,0,-2,0,0,WP4949,16p11 2 proximal deletion syndrome,M100,1,0
0,1,0,0,-4.8,0,GO:2000147,positive regulation of cell motility,M010,1,0
0,0,1,0,0,-2,GO:0030219,megakaryocyte differentiation,M001,1,0
1,0,0,-2.4,0,0,GO:0060070,canonical Wnt signaling pathway,M100,1,0
0,1,0,0,-2.4,0,R-HSA-9664873,Pexophagy,M010,1,0
1,0,0,-2.8,0,0,WP4760,PKC gamma calcium signaling pathway in ataxia,M100,1,0
0,0,1,0,0,-2.1,GO:0030168,platelet activation,M001,1,0
0,1,0,0,-3.3,0,GO:0090184,positive regulation of kidney development,M010,1,0
1,0,0,-2.4,0,0,GO:0003222,ventricular trabecula myocardium morphogenesis,M100,1,0
1,0,0,-2.1,0,0,GO:1905332,positive regulation of morphogenesis of an epithelium,M100,1,0
0,0,1,0,0,-2.1,hsa05217,Basal cell carcinoma,M001,1,0
1,0,0,-2.8,0,0,GO:0090100,positive regulation of transmembrane receptor protein serine/threonine kinase signaling pathway,M100,1,0
1,0,0,-2.4,0,0,R-HSA-5619507,Activation of HOX genes during differentiation,M100,1,0
0,1,0,0,-2.5,0,GO:0022604,regulation of cell morphogenesis,M010,1,0
0,1,0,0,-2.4,0,GO:1902255,positive regulation of intrinsic apoptotic signaling pathway by p53 class mediator,M010,1,0
0,1,0,0,-2.8,0,GO:0060986,endocrine hormone secretion,M010,1,0
0,0,1,0,0,-2.9,hsa04024,cAMP signaling pathway,M001,1,0
0,0,1,0,0,-2.6,GO:0021795,cerebral cortex cell migration,M001,1,0
1,0,0,-2.5,0,0,hsa04710,Circadian rhythm,M100,1,0
1,0,0,-2.1,0,0,GO:0014812,muscle cell migration,M100,1,0
0,1,0,0,-2.4,0,R-HSA-2122947,NOTCH1 Intracellular Domain Regulates Transcription,M010,1,0
1,0,0,-2.8,0,0,GO:0048821,erythrocyte development,M100,1,0
0,1,0,0,-2.2,0,GO:0120035,regulation of plasma membrane bounded cell projection organization,M010,1,0
0,1,0,0,-3.9,0,GO:0023061,signal release,M010,1,0
1,0,0,-2.4,0,0,R-HSA-8941856,RUNX3 regulates NOTCH signaling,M100,1,0
0,1,0,0,-2.5,0,GO:0002704,negative regulation of leukocyte mediated immunity,M010,1,0
0,0,1,0,0,-3.7,GO:0097094,craniofacial suture morphogenesis,M001,1,0
1,0,0,-2.1,0,0,GO:1900046,regulation of hemostasis,M100,1,0
0,1,0,0,-2,0,GO:0072170,metanephric tubule development,M010,1,0
1,0,0,-2.8,0,0,GO:0071357,cellular response to type I interferon,M100,1,0
0,1,0,0,-2.8,0,GO:0007413,axonal fasciculation,M010,1,0
0,1,0,0,-2.6,0,GO:0009914,hormone transport,M010,1,0
0,1,0,0,-2.4,0,R-HSA-9020558,Interleukin-2 signaling,M010,1,0
0,0,1,0,0,-2.5,R-HSA-428542,Regulation of commissural axon pathfinding by SLIT and ROBO,M001,1,0
0,0,1,0,0,-3,WP3858,Toll like receptor signaling related to MyD88,M001,1,0
0,0,1,0,0,-2.7,GO:0007229,integrin-mediated signaling pathway,M001,1,0
0,1,0,0,-2.4,0,GO:0050921,positive regulation of chemotaxis,M010,1,0
0,1,0,0,-2.2,0,R-HSA-936964,"Activation of IRF3, IRF7 mediated by TBK1, IKBKE",M010,1,0
0,0,1,0,0,-2.4,GO:0060135,maternal process involved in female pregnancy,M001,1,0
1,0,0,-2.3,0,0,WP4658,Small cell lung cancer,M100,1,0
1,0,0,-2.4,0,0,WP4481,Resistin as a regulator of inflammation,M100,1,0
0,1,0,0,-2.1,0,GO:0010810,regulation of cell-substrate adhesion,M010,1,0
0,1,0,0,-5.2,0,GO:0022408,negative regulation of cell-cell adhesion,M010,1,0
1,0,0,-4.7,0,0,R-HSA-3108232,SUMO E3 ligases SUMOylate target proteins,M100,1,0
1,0,0,-4.6,0,0,GO:0051091,positive regulation of DNA-binding transcription factor activity,M100,1,0
0,1,0,0,-2,0,GO:1903243,negative regulation of cardiac muscle hypertrophy in response to stress,M010,1,0
1,0,0,-2.2,0,0,GO:0007435,salivary gland morphogenesis,M100,1,0
1,0,0,-2.8,0,0,R-HSA-202430,Translocation of ZAP-70 to Immunological synapse,M100,1,0
1,0,0,-2.1,0,0,GO:0071453,cellular response to oxygen levels,M100,1,0
0,1,0,0,-2.4,0,WP4746,Thyroid hormones production and peripheral downstream signaling effects,M010,1,0
1,0,0,-2.4,0,0,GO:0097720,calcineurin-mediated signaling,M100,1,0
0,0,1,0,0,-2.5,R-HSA-2022870,Chondroitin sulfate biosynthesis,M001,1,0
1,0,0,-2.8,0,0,GO:0043392,negative regulation of DNA binding,M100,1,0
1,0,0,-4.9,0,0,GO:0009299,mRNA transcription,M100,1,0
0,1,0,0,-2,0,GO:0045630,positive regulation of T-helper 2 cell differentiation,M010,1,0
1,0,0,-2.6,0,0,GO:1903034,regulation of response to wounding,M100,1,0
0,0,1,0,0,-2.1,GO:0021846,cell proliferation in forebrain,M001,1,0
0,0,1,0,0,-2.2,GO:0045475,locomotor rhythm,M001,1,0
1,0,0,-2.9,0,0,GO:0021542,dentate gyrus development,M100,1,0
1,0,0,-2.8,0,0,GO:0009187,cyclic nucleotide metabolic process,M100,1,0
0,1,0,0,-2.8,0,WP3947,Serotonin and anxiety,M010,1,0
1,0,0,-2.3,0,0,GO:0048644,muscle organ morphogenesis,M100,1,0
1,0,0,-2.4,0,0,GO:0019370,leukotriene biosynthetic process,M100,1,0
1,0,0,-2.2,0,0,GO:0061384,heart trabecula morphogenesis,M100,1,0
1,0,0,-4.4,0,0,WP2023,Cell differentiation expanded index,M100,1,0
1,0,0,-2.9,0,0,GO:0007584,response to nutrient,M100,1,0
0,0,1,0,0,-3.2,WP5072,Modulators of TCR signaling and T cell activation,M001,1,0
0,1,0,0,-2,0,GO:0001658,branching involved in ureteric bud morphogenesis,M010,1,0
1,0,0,-2.4,0,0,GO:0060438,trachea development,M100,1,0
0,1,0,0,-2.7,0,GO:0008585,female gonad development,M010,1,0
0,0,1,0,0,-2.5,GO:0021889,olfactory bulb interneuron differentiation,M001,1,0
0,0,1,0,0,-2.2,GO:0051414,response to cortisol,M001,1,0
0,1,0,0,-3,0,GO:1902074,response to salt,M010,1,0
1,0,0,-4.5,0,0,WP4331,Neovascularisation processes,M100,1,0
1,0,0,-2.1,0,0,GO:0036314,response to sterol,M100,1,0
0,1,0,0,-2.1,0,WP2877,Vitamin D receptor pathway,M010,1,0
1,0,0,-3.9,0,0,GO:0098727,maintenance of cell number,M100,1,0
0,0,1,0,0,-2.6,R-HSA-1793185,Chondroitin sulfate/dermatan sulfate metabolism,M001,1,0
0,1,0,0,-2,0,GO:0090037,positive regulation of protein kinase C signaling,M010,1,0
0,1,0,0,-5,0,GO:0045622,regulation of T-helper cell differentiation,M010,1,0
1,0,0,-2.4,0,0,GO:0002714,positive regulation of B cell mediated immunity,M100,1,0
1,0,0,-4.8,0,0,WP3995,Prion disease pathway,M100,1,0
0,0,1,0,0,-2.2,R-HSA-9027276,Erythropoietin activates Phosphoinositide-3-kinase (PI3K),M001,1,0
1,0,0,-2.8,0,0,R-HSA-8878171,Transcriptional regulation by RUNX1,M100,1,0
1,0,0,-3.3,0,0,GO:0030178,negative regulation of Wnt signaling pathway,M100,1,0
1,0,0,-2.6,0,0,GO:0033121,regulation of purine nucleotide catabolic process,M100,1,0
1,0,0,-2.1,0,0,WP3651,Pathways affected in adenoid cystic carcinoma,M100,1,0
0,0,1,0,0,-2.9,GO:0050670,regulation of lymphocyte proliferation,M001,1,0
0,1,0,0,-2,0,GO:0072126,positive regulation of glomerular mesangial cell proliferation,M010,1,0
0,0,1,0,0,-2.1,GO:0003184,pulmonary valve morphogenesis,M001,1,0
1,0,0,-2,0,0,WP4877,Host pathogen interaction of human coronaviruses MAPK signaling,M100,1,0
1,0,0,-2.1,0,0,R-HSA-210993,Tie2 Signaling,M100,1,0
0,1,0,0,-2.8,0,GO:0008217,regulation of blood pressure,M010,1,0
0,1,0,0,-2,0,WP3924,Hfe effect on hepcidin production,M010,1,0
1,0,0,-2.4,0,0,hsa04145,Phagosome,M100,1,0
1,0,0,-2.1,0,0,R-HSA-9614085,FOXO-mediated transcription,M100,1,0
0,0,1,0,0,-2.5,GO:0021514,ventral spinal cord interneuron differentiation,M001,1,0
0,1,0,0,-2.2,0,GO:0061008,hepaticobiliary system development,M010,1,0
0,0,1,0,0,-2,R-HSA-9725370,Signaling by ALK fusions and activated point mutants,M001,1,0
1,0,0,-2.1,0,0,GO:1901989,positive regulation of cell cycle phase transition,M100,1,0
1,0,0,-2.4,0,0,GO:0030595,leukocyte chemotaxis,M100,1,0
1,0,0,-3.6,0,0,WP399,Wnt signaling pathway and pluripotency,M100,1,0
1,0,0,-3.7,0,0,M254,PID MYC REPRESS PATHWAY,M100,1,0
1,0,0,-2.4,0,0,GO:0052652,cyclic purine nucleotide metabolic process,M100,1,0
0,1,0,0,-2.4,0,GO:0002825,regulation of T-helper 1 type immune response,M010,1,0
1,0,0,-4.3,0,0,GO:2000181,negative regulation of blood vessel morphogenesis,M100,1,0
1,0,0,-2.2,0,0,GO:0001816,cytokine production,M100,1,0
0,1,0,0,-2.1,0,GO:0051493,regulation of cytoskeleton organization,M010,1,0
1,0,0,-3.9,0,0,GO:0003176,aortic valve development,M100,1,0
0,1,0,0,-4.5,0,GO:0040017,positive regulation of locomotion,M010,1,0
0,1,0,0,-2.1,0,GO:0090189,regulation of branching involved in ureteric bud morphogenesis,M010,1,0
0,0,1,0,0,-3.2,R-HSA-376172,DSCAM interactions,M001,1,0
0,1,0,0,-2.1,0,GO:0002090,regulation of receptor internalization,M010,1,0
1,0,0,-2.9,0,0,R-HSA-9669938,Signaling by KIT in disease,M100,1,0
0,0,1,0,0,-2.3,R-HSA-194315,Signaling by Rho GTPases,M001,1,0
0,1,0,0,-2.7,0,GO:0050808,synapse organization,M010,1,0
1,0,0,-2.5,0,0,WP4241,Type 2 papillary renal cell carcinoma,M100,1,0
0,1,0,0,-2.3,0,GO:0014033,neural crest cell differentiation,M010,1,0
0,1,0,0,-2,0,GO:0033194,response to hydroperoxide,M010,1,0
1,0,0,-2.4,0,0,R-HSA-3232118,SUMOylation of transcription factors,M100,1,0
0,1,0,0,-2.9,0,GO:0001938,positive regulation of endothelial cell proliferation,M010,1,0
1,0,0,-2.1,0,0,GO:0034504,protein localization to nucleus,M100,1,0
0,0,1,0,0,-3.2,WP3967,miR 509 3p alteration of YAP1 ECM axis,M001,1,0
0,1,0,0,-2.1,0,GO:0043113,receptor clustering,M010,1,0
0,1,0,0,-2,0,GO:0003310,pancreatic A cell differentiation,M010,1,0
0,1,0,0,-3.7,0,GO:0007162,negative regulation of cell adhesion,M010,1,0
1,0,0,-2.9,0,0,R-HSA-9013508,NOTCH3 Intracellular Domain Regulates Transcription,M100,1,0
0,1,0,0,-2.5,0,GO:0050671,positive regulation of lymphocyte proliferation,M010,1,0
0,1,0,0,-2.5,0,R-HSA-1980143,Signaling by NOTCH1,M010,1,0
1,0,0,-3.3,0,0,GO:0014014,negative regulation of gliogenesis,M100,1,0
1,0,0,-3.2,0,0,WP4756,Renin angiotensin aldosterone system RAAS,M100,1,0
0,0,1,0,0,-3.2,GO:0043087,regulation of GTPase activity,M001,1,0
0,1,0,0,-2.7,0,GO:0071696,ectodermal placode development,M010,1,0
1,0,0,-2.9,0,0,GO:0002705,positive regulation of leukocyte mediated immunity,M100,1,0
0,1,0,0,-2,0,GO:0010817,regulation of hormone levels,M010,1,0
1,0,0,-2.1,0,0,GO:0021546,rhombomere development,M100,1,0
1,0,0,-2.3,0,0,hsa03083,Polycomb repressive complex,M100,1,0
0,0,1,0,0,-2.6,GO:0070663,regulation of leukocyte proliferation,M001,1,0
0,1,0,0,-2.9,0,GO:0071351,cellular response to interleukin-18,M010,1,0
0,0,1,0,0,-2.1,GO:0010743,regulation of macrophage derived foam cell differentiation,M001,1,0
1,0,0,-2.5,0,0,GO:2000379,positive regulation of reactive oxygen species metabolic process,M100,1,0
0,1,0,0,-2.8,0,R-HSA-170834,Signaling by TGF-beta Receptor Complex,M010,1,0
0,1,0,0,-2.6,0,GO:0045765,regulation of angiogenesis,M010,1,0
1,0,0,-2.4,0,0,M41,PID ER NONGENOMIC PATHWAY,M100,1,0
0,1,0,0,-2.4,0,GO:0072088,nephron epithelium morphogenesis,M010,1,0
1,0,0,-3.4,0,0,GO:0002399,MHC class II protein complex assembly,M100,1,0
0,1,0,0,-3.7,0,GO:0099536,synaptic signaling,M010,1,0
1,0,0,-2.5,0,0,hsa05330,Allograft rejection,M100,1,0
1,0,0,-2.2,0,0,GO:1905953,negative regulation of lipid localization,M100,1,0
1,0,0,-2,0,0,WP4871,Kisspeptin kisspeptin receptor system in the ovary,M100,1,0
1,0,0,-3.6,0,0,GO:0051058,negative regulation of small GTPase mediated signal transduction,M100,1,0
1,0,0,-6.7,0,0,GO:0006109,regulation of carbohydrate metabolic process,M100,1,0
1,0,0,-5.2,0,0,GO:0050768,negative regulation of neurogenesis,M100,1,0
1,0,0,-2.8,0,0,WP4538,Regulatory circuits of the STAT3 signaling pathway,M100,1,0
1,0,0,-2.9,0,0,GO:1990823,response to leukemia inhibitory factor,M100,1,0
0,1,0,0,-2,0,R-HSA-8948747,Regulation of PTEN localization,M010,1,0
0,1,0,0,-2,0,GO:0010566,regulation of ketone biosynthetic process,M010,1,0
1,0,0,-2.8,0,0,GO:0009267,cellular response to starvation,M100,1,0
1,0,0,-2,0,0,GO:0035329,hippo signaling,M100,1,0
1,0,0,-3.6,0,0,GO:0046620,regulation of organ growth,M100,1,0
0,1,0,0,-2.1,0,R-HSA-2262752,Cellular responses to stress,M010,1,0
1,0,0,-2.9,0,0,GO:0046425,regulation of receptor signaling pathway via JAK-STAT,M100,1,0
0,1,0,0,-3.3,0,GO:0035767,endothelial cell chemotaxis,M010,1,0
1,0,0,-4.4,0,0,hsa05145,Toxoplasmosis,M100,1,0
0,1,0,0,-2.1,0,GO:0060674,placenta blood vessel development,M010,1,0
1,0,0,-3.4,0,0,hsa05160,Hepatitis C,M100,1,0
1,0,0,-4.1,0,0,GO:0001959,regulation of cytokine-mediated signaling pathway,M100,1,0
0,0,1,0,0,-2.6,GO:0010837,regulation of keratinocyte proliferation,M001,1,0
0,0,1,0,0,-2.3,GO:0042129,regulation of T cell proliferation,M001,1,0
0,1,0,0,-2,0,GO:0002826,negative regulation of T-helper 1 type immune response,M010,1,0
1,0,0,-2.6,0,0,GO:0060534,trachea cartilage development,M100,1,0
1,0,0,-2,0,0,hsa04940,Type I diabetes mellitus,M100,1,0
0,0,1,0,0,-3.1,WP4357,NRF2 ARE regulation,M001,1,0
1,0,0,-2.9,0,0,GO:0090068,positive regulation of cell cycle process,M100,1,0
0,0,1,0,0,-2.6,hsa03320,PPAR signaling pathway,M001,1,0
1,0,0,-2.6,0,0,GO:0030811,regulation of nucleotide catabolic process,M100,1,0
1,0,0,-2.1,0,0,GO:0061551,trigeminal ganglion development,M100,1,0
1,0,0,-4.6,0,0,GO:0006984,ER-nucleus signaling pathway,M100,1,0
1,0,0,-2.4,0,0,M13,PID ERBB4 PATHWAY,M100,1,0
1,0,0,-2.4,0,0,R-HSA-9648895,Response of EIF2AK1 (HRI) to heme deficiency,M100,1,0
0,0,1,0,0,-2.6,GO:0050923,regulation of negative chemotaxis,M001,1,0
0,1,0,0,-2.7,0,GO:0050804,modulation of chemical synaptic transmission,M010,1,0
1,0,0,-2.2,0,0,GO:0060420,regulation of heart growth,M100,1,0
1,0,0,-4.9,0,0,GO:0009991,response to extracellular stimulus,M100,1,0
0,0,1,0,0,-3,GO:0008589,regulation of smoothened signaling pathway,M001,1,0
1,0,0,-2.7,0,0,GO:0060350,endochondral bone morphogenesis,M100,1,0
0,1,0,0,-2.4,0,GO:0060479,lung cell differentiation,M010,1,0
0,1,0,0,-2.2,0,GO:0044782,cilium organization,M010,1,0
1,0,0,-3.2,0,0,WP4263,Pancreatic adenocarcinoma pathway,M100,1,0
1,0,0,-5.4,0,0,WP400,p38 MAPK signaling pathway,M100,1,0
1,0,0,-4.1,0,0,GO:0048592,eye morphogenesis,M100,1,0
1,0,0,-2.1,0,0,GO:0060685,regulation of prostatic bud formation,M100,1,0
0,1,0,0,-2.2,0,GO:0060872,semicircular canal development,M010,1,0
1,0,0,-2.4,0,0,GO:0003208,cardiac ventricle morphogenesis,M100,1,0
0,1,0,0,-2,0,GO:0050830,defense response to Gram-positive bacterium,M010,1,0
0,1,0,0,-6.2,0,R-HSA-2029485,Role of phospholipids in phagocytosis,M010,1,0
1,0,0,-2.6,0,0,GO:0022028,tangential migration from the subventricular zone to the olfactory bulb,M100,1,0
0,0,1,0,0,-2.6,R-HSA-373752,Netrin-1 signaling,M001,1,0
0,0,1,0,0,-2.1,GO:0031294,lymphocyte costimulation,M001,1,0
1,0,0,-2,0,0,WP3614,Photodynamic therapy induced HIF 1 survival signaling,M100,1,0
1,0,0,-2,0,0,GO:0045923,positive regulation of fatty acid metabolic process,M100,1,0
1,0,0,-2.8,0,0,R-HSA-380994,ATF4 activates genes in response to endoplasmic reticulum  stress,M100,1,0
1,0,0,-3,0,0,GO:0043524,negative regulation of neuron apoptotic process,M100,1,0
1,0,0,-2.6,0,0,GO:0097011,cellular response to granulocyte macrophage colony-stimulating factor stimulus,M100,1,0
0,1,0,0,-2.4,0,GO:1904407,positive regulation of nitric oxide metabolic process,M010,1,0
1,0,0,-2.6,0,0,GO:0046015,regulation of transcription by glucose,M100,1,0
0,1,0,0,-2.4,0,GO:0060214,endocardium formation,M010,1,0
0,1,0,0,-2.2,0,GO:0098743,cell aggregation,M010,1,0
0,1,0,0,-2.4,0,GO:0038001,paracrine signaling,M010,1,0
0,0,1,0,0,-2.5,WP3612,Photodynamic therapy induced NFE2L2 NRF2 survival signaling,M001,1,0
1,0,0,-3.4,0,0,GO:0002698,negative regulation of immune effector process,M100,1,0
1,0,0,-5.3,0,0,GO:0045600,positive regulation of fat cell differentiation,M100,1,0
1,0,0,-2.8,0,0,GO:0043467,regulation of generation of precursor metabolites and energy,M100,1,0
1,0,0,-3.2,0,0,R-HSA-381042,PERK regulates gene expression,M100,1,0
1,0,0,-2.1,0,0,hsa04672,Intestinal immune network for IgA production,M100,1,0
1,0,0,-2.4,0,0,GO:0033238,regulation of amine metabolic process,M100,1,0
0,0,1,0,0,-3.6,R-HSA-9027284,Erythropoietin activates RAS,M001,1,0
1,0,0,-2.1,0,0,GO:1903350,response to dopamine,M100,1,0
0,0,1,0,0,-2,hsa04012,ErbB signaling pathway,M001,1,0
1,0,0,-2.2,0,0,WP4932,7q11 23 copy number variation syndrome,M100,1,0
1,0,0,-2.1,0,0,GO:0006919,activation of cysteine-type endopeptidase activity involved in apoptotic process,M100,1,0
0,1,0,0,-2.1,0,GO:0045773,positive regulation of axon extension,M010,1,0
1,0,0,-5.7,0,0,hsa04926,Relaxin signaling pathway,M100,1,0
0,1,0,0,-3,0,GO:0061081,positive regulation of myeloid leukocyte cytokine production involved in immune response,M010,1,0
0,1,0,0,-2.2,0,GO:0021561,facial nerve development,M010,1,0
0,1,0,0,-2.4,0,GO:0060018,astrocyte fate commitment,M010,1,0
1,0,0,-3.2,0,0,GO:0002448,mast cell mediated immunity,M100,1,0
0,1,0,0,-2.1,0,R-HSA-9013404,RAC2 GTPase cycle,M010,1,0
0,0,1,0,0,-2.2,WP364,IL6 signaling pathway,M001,1,0
0,1,0,0,-2.5,0,GO:0090092,regulation of transmembrane receptor protein serine/threonine kinase signaling pathway,M010,1,0
1,0,0,-4.5,0,0,GO:0003180,aortic valve morphogenesis,M100,1,0
1,0,0,-3.7,0,0,hsa04934,Cushing syndrome,M100,1,0
0,0,1,0,0,-3.2,GO:0032747,positive regulation of interleukin-23 production,M001,1,0
0,1,0,0,-2.3,0,GO:0007200,phospholipase C-activating G protein-coupled receptor signaling pathway,M010,1,0
0,1,0,0,-2.4,0,CORUM:2754,JUND-FOSB-SMAD3-SMAD4 complex,M010,1,0
0,1,0,0,-2.4,0,GO:0032703,negative regulation of interleukin-2 production,M010,1,0
0,1,0,0,-3.2,0,M63,PID AVB3 OPN PATHWAY,M010,1,0
1,0,0,-5.5,0,0,GO:1902532,negative regulation of intracellular signal transduction,M100,1,0
0,1,0,0,-2.8,0,GO:0001823,mesonephros development,M010,1,0
0,1,0,0,-2,0,R-HSA-2151201,Transcriptional activation of mitochondrial biogenesis,M010,1,0
1,0,0,-2,0,0,GO:0051099,positive regulation of binding,M100,1,0
1,0,0,-2.4,0,0,R-HSA-1839117,Signaling by cytosolic FGFR1 fusion mutants,M100,1,0
1,0,0,-3.7,0,0,WP734,Serotonin receptor 4 6 7 and NR3C signaling,M100,1,0
0,1,0,0,-2.3,0,GO:0060907,positive regulation of macrophage cytokine production,M010,1,0
1,0,0,-2.1,0,0,GO:0060688,regulation of morphogenesis of a branching structure,M100,1,0
1,0,0,-2.8,0,0,GO:0060325,face morphogenesis,M100,1,0
1,0,0,-2.1,0,0,hsa04750,Inflammatory mediator regulation of TRP channels,M100,1,0
1,0,0,-3.7,0,0,WP304,Kit receptor signaling pathway,M100,1,0
1,0,0,-6.5,0,0,GO:0048545,response to steroid hormone,M100,1,0
0,0,1,0,0,-2.8,GO:0097028,dendritic cell differentiation,M001,1,0
0,0,1,0,0,-3.2,GO:0034775,glutathione transmembrane transport,M001,1,0
1,0,0,-2.2,0,0,WP138,Androgen receptor signaling pathway,M100,1,0
1,0,0,-2.4,0,0,GO:0045682,regulation of epidermis development,M100,1,0
1,0,0,-2.5,0,0,hsa04919,Thyroid hormone signaling pathway,M100,1,0
1,0,0,-3.6,0,0,WP2431,Spinal cord injury,M100,1,0
0,1,0,0,-2.2,0,GO:0045198,establishment of epithelial cell apical/basal polarity,M010,1,0
0,1,0,0,-2.3,0,GO:0051100,negative regulation of binding,M010,1,0
0,1,0,0,-2.7,0,hsa04151,PI3K-Akt signaling pathway,M010,1,0
0,1,0,0,-2.2,0,GO:0002687,positive regulation of leukocyte migration,M010,1,0
0,0,1,0,0,-3.4,hsa05135,Yersinia infection,M001,1,0
0,1,0,0,-2.4,0,GO:0032946,positive regulation of mononuclear cell proliferation,M010,1,0
0,0,1,0,0,-2,R-HSA-9772573,Late SARS-CoV-2 Infection Events,M001,1,0
1,0,0,-3.4,0,0,GO:0048661,positive regulation of smooth muscle cell proliferation,M100,1,0
1,0,0,-4,0,0,GO:0030902,hindbrain development,M100,1,0
0,0,1,0,0,-2.3,GO:0050772,positive regulation of axonogenesis,M001,1,0
1,0,0,-2.4,0,0,hsa05322,Systemic lupus erythematosus,M100,1,0
1,0,0,-2.5,0,0,GO:0035148,tube formation,M100,1,0
0,0,1,0,0,-2.2,GO:0036446,myofibroblast differentiation,M001,1,0
0,1,0,0,-2.1,0,M12,PID RHOA PATHWAY,M010,1,0
0,0,1,0,0,-2.5,WP3630,NAD metabolism sirtuins and aging,M001,1,0
0,1,0,0,-3.4,0,GO:0031401,positive regulation of protein modification process,M010,1,0
0,0,1,0,0,-3.1,M175,PID ERBB2 ERBB3 PATHWAY,M001,1,0
1,0,0,-2.4,0,0,GO:0045685,regulation of glial cell differentiation,M100,1,0
1,0,0,-3.8,0,0,hsa04921,Oxytocin signaling pathway,M100,1,0
0,1,0,0,-2.4,0,GO:0072171,mesonephric tubule morphogenesis,M010,1,0
0,1,0,0,-2.1,0,GO:0032649,regulation of type II interferon production,M010,1,0
1,0,0,-3.2,0,0,GO:0035137,hindlimb morphogenesis,M100,1,0
0,0,1,0,0,-3.2,GO:0021965,spinal cord ventral commissure morphogenesis,M001,1,0
1,0,0,-5.6,0,0,WP2526,PDGF pathway,M100,1,0
1,0,0,-2.1,0,0,GO:0000430,regulation of transcription from RNA polymerase II promoter by glucose,M100,1,0
0,1,0,0,-6,0,GO:0050900,leukocyte migration,M010,1,0
1,0,0,-2.9,0,0,R-HSA-8943724,Regulation of PTEN gene transcription,M100,1,0
1,0,0,-4.8,0,0,GO:1901654,response to ketone,M100,1,0
1,0,0,-2.5,0,0,GO:0007431,salivary gland development,M100,1,0
1,0,0,-3.2,0,0,R-HSA-8864260,Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors,M100,1,0
0,0,1,0,0,-3.2,GO:1902869,regulation of amacrine cell differentiation,M001,1,0
1,0,0,-2.1,0,0,GO:0071499,cellular response to laminar fluid shear stress,M100,1,0
1,0,0,-2.4,0,0,GO:0060749,mammary gland alveolus development,M100,1,0
1,0,0,-2.8,0,0,GO:0071404,cellular response to low-density lipoprotein particle stimulus,M100,1,0
0,1,0,0,-2.5,0,GO:0042327,positive regulation of phosphorylation,M010,1,0
0,1,0,0,-2.2,0,GO:1904672,regulation of somatic stem cell population maintenance,M010,1,0
0,0,1,0,0,-3,GO:0009954,proximal/distal pattern formation,M001,1,0
1,0,0,-2.9,0,0,M91,PID TCPTP PATHWAY,M100,1,0
0,1,0,0,-3.3,0,GO:0048871,multicellular organismal-level homeostasis,M010,1,0
1,0,0,-5,0,0,WP382,MAPK signaling pathway,M100,1,0
0,1,0,0,-2.7,0,R-HSA-112316,Neuronal System,M010,1,0
0,1,0,0,-2,0,WP2035,Follicle stimulating hormone FSH signaling pathway,M010,1,0
0,1,0,0,-2.5,0,GO:0014745,negative regulation of muscle adaptation,M010,1,0
0,0,1,0,0,-2.6,R-HSA-9694631,Maturation of nucleoprotein,M001,1,0
0,1,0,0,-4,0,GO:0045766,positive regulation of angiogenesis,M010,1,0
1,0,0,-4.9,0,0,GO:0031667,response to nutrient levels,M100,1,0
1,0,0,-2.2,0,0,GO:0051148,negative regulation of muscle cell differentiation,M100,1,0
1,0,0,-2.6,0,0,GO:1905330,regulation of morphogenesis of an epithelium,M100,1,0
1,0,0,-2.1,0,0,GO:0001574,ganglioside biosynthetic process,M100,1,0
1,0,0,-4.2,0,0,GO:0031669,cellular response to nutrient levels,M100,1,0
0,1,0,0,-2.4,0,GO:1903589,positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis,M010,1,0
0,0,1,0,0,-2.6,GO:0032743,positive regulation of interleukin-2 production,M001,1,0
0,1,0,0,-2,0,hsa04510,Focal adhesion,M010,1,0
1,0,0,-3.4,0,0,GO:0061041,regulation of wound healing,M100,1,0
1,0,0,-2.2,0,0,R-HSA-3000170,Syndecan interactions,M100,1,0
0,0,1,0,0,-2.6,WP313,Hepatocyte growth factor receptor signaling,M001,1,0
0,1,0,0,-2.2,0,GO:0014741,negative regulation of muscle hypertrophy,M010,1,0
1,0,0,-2.1,0,0,WP3407,FTO obesity variant mechanism,M100,1,0
0,0,1,0,0,-2.1,WP4155,Endometrial cancer,M001,1,0
0,1,0,0,-2.2,0,GO:0001502,cartilage condensation,M010,1,0
0,1,0,0,-3.1,0,GO:0090257,regulation of muscle system process,M010,1,0
1,0,0,-2,0,0,GO:0014037,Schwann cell differentiation,M100,1,0
1,0,0,-4.6,0,0,GO:0043535,regulation of blood vessel endothelial cell migration,M100,1,0
0,1,0,0,-4.4,0,GO:0050731,positive regulation of peptidyl-tyrosine phosphorylation,M010,1,0
1,0,0,-2.1,0,0,hsa04144,Endocytosis,M100,1,0
1,0,0,-2.5,0,0,WP4313,Ferroptosis,M100,1,0
1,0,0,-4.6,0,0,GO:0071466,cellular response to xenobiotic stimulus,M100,1,0
0,1,0,0,-2,0,GO:0060788,ectodermal placode formation,M010,1,0
1,0,0,-4.3,0,0,GO:0046578,regulation of Ras protein signal transduction,M100,1,0
1,0,0,-2.2,0,0,GO:0048864,stem cell development,M100,1,0
1,0,0,-2.1,0,0,GO:0001824,blastocyst development,M100,1,0
0,1,0,0,-2.2,0,GO:0071870,cellular response to catecholamine stimulus,M010,1,0
1,0,0,-4.5,0,0,hsa04630,JAK-STAT signaling pathway,M100,1,0
1,0,0,-2.5,0,0,GO:2001235,positive regulation of apoptotic signaling pathway,M100,1,0
1,0,0,-2.4,0,0,GO:0007422,peripheral nervous system development,M100,1,0
0,1,0,0,-2.2,0,GO:0032814,regulation of natural killer cell activation,M010,1,0
1,0,0,-2.1,0,0,WP4880,Host pathogen interaction of human coronaviruses interferon induction,M100,1,0
1,0,0,-2.8,0,0,GO:0071391,cellular response to estrogen stimulus,M100,1,0
0,1,0,0,-2.7,0,GO:0046636,negative regulation of alpha-beta T cell activation,M010,1,0
1,0,0,-2.4,0,0,R-HSA-381183,ATF6 (ATF6-alpha) activates chaperone genes,M100,1,0
0,1,0,0,-2.4,0,GO:0072078,nephron tubule morphogenesis,M010,1,0
0,0,1,0,0,-2,R-HSA-9700206,Signaling by ALK in cancer,M001,1,0
0,1,0,0,-3.3,0,R-HSA-2173793,Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer,M010,1,0
1,0,0,-3.2,0,0,GO:0043313,regulation of neutrophil degranulation,M100,1,0
0,0,1,0,0,-3.2,GO:0032667,regulation of interleukin-23 production,M001,1,0
0,0,1,0,0,-2.3,hsa04620,Toll-like receptor signaling pathway,M001,1,0
1,0,0,-2.5,0,0,GO:0030534,adult behavior,M100,1,0
0,1,0,0,-2.6,0,GO:0002819,regulation of adaptive immune response,M010,1,0
1,0,0,-2.1,0,0,GO:0030193,regulation of blood coagulation,M100,1,0
1,0,0,-4,0,0,GO:0032680,regulation of tumor necrosis factor production,M100,1,0
1,0,0,-2,0,0,GO:0003401,axis elongation,M100,1,0
1,0,0,-2,0,0,GO:0060425,lung morphogenesis,M100,1,0
1,0,0,-5,0,0,hsa04066,HIF-1 signaling pathway,M100,1,0
0,1,0,0,-2.2,0,GO:0002820,negative regulation of adaptive immune response,M010,1,0
1,0,0,-2,0,0,M210,PID IL8 CXCR2 PATHWAY,M100,1,0
1,0,0,-2.2,0,0,GO:0060415,muscle tissue morphogenesis,M100,1,0
1,0,0,-2.9,0,0,R-HSA-8866910,TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,M100,1,0
1,0,0,-3.4,0,0,GO:0198738,cell-cell signaling by wnt,M100,1,0
0,1,0,0,-2.5,0,R-HSA-418594,G alpha (i) signalling events,M010,1,0
0,0,1,0,0,-2.6,GO:0010885,regulation of cholesterol storage,M001,1,0
0,1,0,0,-2.2,0,R-HSA-4641265,Repression of WNT target genes,M010,1,0
0,1,0,0,-2.3,0,GO:0034341,response to type II interferon,M010,1,0
1,0,0,-7.2,0,0,GO:0062012,regulation of small molecule metabolic process,M100,1,0
1,0,0,-3.2,0,0,GO:0002495,antigen processing and presentation of peptide antigen via MHC class II,M100,1,0
1,0,0,-2.1,0,0,GO:0060745,mammary gland branching involved in pregnancy,M100,1,0
0,0,1,0,0,-3.7,hsa04360,Axon guidance,M001,1,0
1,0,0,-4.2,0,0,WP2881,Estrogen receptor pathway,M100,1,0
0,1,0,0,-2.4,0,CORUM:2692,SMAD3-SMAD4-cJun-cFos complex,M010,1,0
0,1,0,0,-3.5,0,GO:0042742,defense response to bacterium,M010,1,0
1,0,0,-2.5,0,0,WP98,Prostaglandin synthesis and regulation,M100,1,0
1,0,0,-2.4,0,0,GO:0060351,cartilage development involved in endochondral bone morphogenesis,M100,1,0
0,1,0,0,-2.3,0,GO:0072028,nephron morphogenesis,M010,1,0
0,1,0,0,-3,0,GO:0072163,mesonephric epithelium development,M010,1,0
1,0,0,-2.8,0,0,GO:0003416,endochondral bone growth,M100,1,0
1,0,0,-3.6,0,0,GO:1900542,regulation of purine nucleotide metabolic process,M100,1,0
0,1,0,0,-3.2,0,GO:0099537,trans-synaptic signaling,M010,1,0
1,0,0,-3.5,0,0,GO:0016032,viral process,M100,1,0
0,1,0,0,-2.5,0,GO:0032228,"regulation of synaptic transmission, GABAergic",M010,1,0
0,1,0,0,-2.4,0,GO:0043380,regulation of memory T cell differentiation,M010,1,0
0,0,1,0,0,-2.1,GO:0002200,somatic diversification of immune receptors,M001,1,0
0,0,1,0,0,-3.1,R-HSA-389356,CD28 co-stimulation,M001,1,0
1,0,0,-2.4,0,0,WP4585,Cancer immunotherapy by PD 1 blockade,M100,1,0
1,0,0,-2.8,0,0,GO:0002501,peptide antigen assembly with MHC protein complex,M100,1,0
1,0,0,-2.6,0,0,GO:0009214,cyclic nucleotide catabolic process,M100,1,0
1,0,0,-2.6,0,0,GO:0051048,negative regulation of secretion,M100,1,0
1,0,0,-2.6,0,0,GO:0006110,regulation of glycolytic process,M100,1,0
0,1,0,0,-3.3,0,GO:0071679,commissural neuron axon guidance,M010,1,0
1,0,0,-2.6,0,0,GO:0051384,response to glucocorticoid,M100,1,0
1,0,0,-2.1,0,0,GO:0000432,positive regulation of transcription from RNA polymerase II promoter by glucose,M100,1,0
1,0,0,-2.3,0,0,GO:1902930,regulation of alcohol biosynthetic process,M100,1,0
1,0,0,-2.4,0,0,GO:1902931,negative regulation of alcohol biosynthetic process,M100,1,0
1,0,0,-2.8,0,0,GO:0046546,development of primary male sexual characteristics,M100,1,0
0,1,0,0,-2.2,0,GO:0021533,cell differentiation in hindbrain,M010,1,0
0,0,1,0,0,-3.5,R-HSA-2029482,Regulation of actin dynamics for phagocytic cup formation,M001,1,0
0,1,0,0,-3.3,0,GO:0002830,positive regulation of type 2 immune response,M010,1,0
0,0,1,0,0,-2.3,GO:0098609,cell-cell adhesion,M001,1,0
0,1,0,0,-2.3,0,GO:0061028,establishment of endothelial barrier,M010,1,0
0,1,0,0,-2.6,0,GO:0010811,positive regulation of cell-substrate adhesion,M010,1,0
1,0,0,-2.4,0,0,GO:0002821,positive regulation of adaptive immune response,M100,1,0
1,0,0,-2.8,0,0,GO:0042698,ovulation cycle,M100,1,0
1,0,0,-2.1,0,0,R-HSA-9818035,NFE2L2 regulating ER-stress associated genes,M100,1,0
1,0,0,-3.4,0,0,WP3303,RAC1 PAK1 p38 MMP2 pathway,M100,1,0
1,0,0,-4.7,0,0,WP3584,MECP2 and associated Rett syndrome,M100,1,0
1,0,0,-2,0,0,GO:0002042,cell migration involved in sprouting angiogenesis,M100,1,0
1,0,0,-2.6,0,0,WP3931,Embryonic stem cell pluripotency pathways,M100,1,0
1,0,0,-5.3,0,0,M162,PID RXR VDR PATHWAY,M100,1,0
0,1,0,0,-2.1,0,GO:0043388,positive regulation of DNA binding,M010,1,0
1,0,0,-4,0,0,GO:0043537,negative regulation of blood vessel endothelial cell migration,M100,1,0
0,1,0,0,-2.7,0,GO:1901722,regulation of cell proliferation involved in kidney development,M010,1,0
1,0,0,-2.6,0,0,GO:0043536,positive regulation of blood vessel endothelial cell migration,M100,1,0
0,1,0,0,-3,0,GO:0072164,mesonephric tubule development,M010,1,0
1,0,0,-2,0,0,GO:0045807,positive regulation of endocytosis,M100,1,0
0,1,0,0,-2,0,GO:0072234,metanephric nephron tubule development,M010,1,0
1,0,0,-2.3,0,0,GO:0021885,forebrain cell migration,M100,1,0
1,0,0,-3.1,0,0,M5493,WNT SIGNALING,M100,1,0
0,0,1,0,0,-2.2,GO:0050878,regulation of body fluid levels,M001,1,0
1,0,0,-2.3,0,0,R-HSA-3000171,Non-integrin membrane-ECM interactions,M100,1,0
0,1,0,0,-2.8,0,GO:0032970,regulation of actin filament-based process,M010,1,0
0,1,0,0,-3.5,0,GO:0051591,response to cAMP,M010,1,0
1,0,0,-7,0,0,R-HSA-9006931,Signaling by Nuclear Receptors,M100,1,0
1,0,0,-4,0,0,GO:0060759,regulation of response to cytokine stimulus,M100,1,0
0,0,1,0,0,-2.1,GO:0002063,chondrocyte development,M001,1,0
1,0,0,-2.9,0,0,hsa04015,Rap1 signaling pathway,M100,1,0
1,0,0,-2.8,0,0,GO:0045747,positive regulation of Notch signaling pathway,M100,1,0
1,0,0,-2.8,0,0,GO:0032760,positive regulation of tumor necrosis factor production,M100,1,0
0,1,0,0,-2.1,0,GO:0046638,positive regulation of alpha-beta T cell differentiation,M010,1,0
1,0,0,-2.4,0,0,WP1991,SRF and miRs in smooth muscle differentiation and proliferation,M100,1,0
0,1,0,0,-2.7,0,GO:0007548,sex differentiation,M010,1,0
0,1,0,0,-2.5,0,GO:0032695,negative regulation of interleukin-12 production,M010,1,0
1,0,0,-2.4,0,0,GO:0008366,axon ensheathment,M100,1,0
1,0,0,-2.8,0,0,GO:0062014,negative regulation of small molecule metabolic process,M100,1,0
1,0,0,-3.2,0,0,GO:1901862,negative regulation of muscle tissue development,M100,1,0
0,1,0,0,-2,0,GO:0002076,osteoblast development,M010,1,0
0,1,0,0,-2.3,0,GO:1901798,positive regulation of signal transduction by p53 class mediator,M010,1,0
1,0,0,-2.3,0,0,GO:0071456,cellular response to hypoxia,M100,1,0
0,0,1,0,0,-2.5,GO:0003177,pulmonary valve development,M001,1,0
1,0,0,-2.3,0,0,WP2880,Glucocorticoid receptor pathway,M100,1,0
1,0,0,-2.8,0,0,GO:0002279,mast cell activation involved in immune response,M100,1,0
1,0,0,-3.7,0,0,hsa04927,Cortisol synthesis and secretion,M100,1,0
0,1,0,0,-3.3,0,GO:0071599,otic vesicle development,M010,1,0
1,0,0,-3.6,0,0,WP3640,Imatinib and chronic myeloid leukemia,M100,1,0
0,1,0,0,-2.1,0,GO:1902903,regulation of supramolecular fiber organization,M010,1,0
1,0,0,-2.1,0,0,GO:0042416,dopamine biosynthetic process,M100,1,0
1,0,0,-2.8,0,0,GO:0060444,branching involved in mammary gland duct morphogenesis,M100,1,0
1,0,0,-2,0,0,GO:0034614,cellular response to reactive oxygen species,M100,1,0
1,0,0,-3.1,0,0,GO:0008406,gonad development,M100,1,0
0,1,0,0,-3.6,0,GO:0032103,positive regulation of response to external stimulus,M010,1,0
1,0,0,-2,0,0,GO:0040014,regulation of multicellular organism growth,M100,1,0
0,1,0,0,-2.9,0,GO:0030832,regulation of actin filament length,M010,1,0
1,0,0,-2.1,0,0,GO:1905331,negative regulation of morphogenesis of an epithelium,M100,1,0
0,1,0,0,-2.1,0,R-HSA-8940973,RUNX2 regulates osteoblast differentiation,M010,1,0
0,1,0,0,-2.2,0,GO:0045927,positive regulation of growth,M010,1,0
1,0,0,-2,0,0,GO:0014032,neural crest cell development,M100,1,0
0,1,0,0,-2.2,0,GO:0048286,lung alveolus development,M010,1,0
0,1,0,0,-2.7,0,R-HSA-201722,Formation of the beta-catenin:TCF transactivating complex,M010,1,0
1,0,0,-2.4,0,0,WP5236,Markers of kidney cell lineage,M100,1,0
0,1,0,0,-2.1,0,GO:0072079,nephron tubule formation,M010,1,0
1,0,0,-2.8,0,0,GO:0071402,cellular response to lipoprotein particle stimulus,M100,1,0
1,0,0,-2.8,0,0,GO:0015914,phospholipid transport,M100,1,0
0,1,0,0,-2.8,0,GO:0010611,regulation of cardiac muscle hypertrophy,M010,1,0
1,0,0,-2.1,0,0,R-HSA-9673770,Signaling by PDGFRA extracellular domain mutants,M100,1,0
0,1,0,0,-2.1,0,M106,PID HNF3B PATHWAY,M010,1,0
0,1,0,0,-2.1,0,GO:0009595,detection of biotic stimulus,M010,1,0
1,0,0,-2.6,0,0,GO:0043030,regulation of macrophage activation,M100,1,0
0,1,0,0,-2.8,0,GO:0032817,regulation of natural killer cell proliferation,M010,1,0
1,0,0,-2.1,0,0,GO:0009629,response to gravity,M100,1,0
0,1,0,0,-2.6,0,GO:0042116,macrophage activation,M010,1,0
1,0,0,-2.3,0,0,GO:0002218,activation of innate immune response,M100,1,0
0,1,0,0,-2.5,0,GO:0080164,regulation of nitric oxide metabolic process,M010,1,0
0,0,1,0,0,-2.3,hsa05130,Pathogenic Escherichia coli infection,M001,1,0
1,0,0,-2.4,0,0,M36,PID IL27 PATHWAY,M100,1,0
1,0,0,-2.5,0,0,hsa04720,Long-term potentiation,M100,1,0
1,0,0,-3,0,0,WP5144,NRP1 triggered signaling pathways in pancreatic cancer,M100,1,0
1,0,0,-4.1,0,0,GO:0001666,response to hypoxia,M100,1,0
1,0,0,-2.1,0,0,hsa05415,Diabetic cardiomyopathy,M100,1,0
0,0,1,0,0,-2,GO:0060043,regulation of cardiac muscle cell proliferation,M001,1,0
0,1,0,0,-2,0,R-HSA-6806834,Signaling by MET,M010,1,0
1,0,0,-2.8,0,0,GO:0002396,MHC protein complex assembly,M100,1,0
0,0,1,0,0,-2.1,GO:0002052,positive regulation of neuroblast proliferation,M001,1,0
1,0,0,-2.9,0,0,GO:0003417,growth plate cartilage development,M100,1,0
1,0,0,-3.6,0,0,M145,PID P53 DOWNSTREAM PATHWAY,M100,1,0
1,0,0,-3.7,0,0,GO:0045936,negative regulation of phosphate metabolic process,M100,1,0
1,0,0,-2.8,0,0,GO:0060337,type I interferon-mediated signaling pathway,M100,1,0
0,1,0,0,-2.7,0,WP1591,Heart development,M010,1,0
1,0,0,-3.4,0,0,GO:0071241,cellular response to inorganic substance,M100,1,0
1,0,0,-2.6,0,0,GO:0090130,tissue migration,M100,1,0
0,0,1,0,0,-2.1,M34,PID TCR PATHWAY,M001,1,0
0,1,0,0,-2.1,0,hsa04730,Long-term depression,M010,1,0
0,1,0,0,-2.8,0,GO:0051966,"regulation of synaptic transmission, glutamatergic",M010,1,0
1,0,0,-2.6,0,0,GO:0008584,male gonad development,M100,1,0
1,0,0,-2.7,0,0,GO:0043470,regulation of carbohydrate catabolic process,M100,1,0
0,1,0,0,-4.5,0,GO:0032673,regulation of interleukin-4 production,M010,1,0
0,1,0,0,-2.4,0,GO:0060627,regulation of vesicle-mediated transport,M010,1,0
0,1,0,0,-2.1,0,GO:0090103,cochlea morphogenesis,M010,1,0
0,1,0,0,-3.7,0,WP516,Hypertrophy model,M010,1,0
1,0,0,-4.1,0,0,GO:0010906,regulation of glucose metabolic process,M100,1,0
1,0,0,-2.8,0,0,WP4535,Envelope proteins and their potential roles in EDMD physiopathology,M100,1,0
0,1,0,0,-2.9,0,GO:0010458,exit from mitosis,M010,1,0
0,1,0,0,-2.9,0,GO:0001934,positive regulation of protein phosphorylation,M010,1,0
1,0,0,-2.5,0,0,GO:1990849,vacuolar localization,M100,1,0
0,0,1,0,0,-2.8,M88,PID CD8 TCR PATHWAY,M001,1,0
0,1,0,0,-2.7,0,GO:0048762,mesenchymal cell differentiation,M010,1,0
1,0,0,-3.7,0,0,GO:0010563,negative regulation of phosphorus metabolic process,M100,1,0
1,0,0,-2.1,0,0,R-HSA-9673767,"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants",M100,1,0
0,1,0,0,-2.1,0,R-HSA-451927,Interleukin-2 family signaling,M010,1,0
1,0,0,-2.1,0,0,GO:0060368,regulation of Fc receptor mediated stimulatory signaling pathway,M100,1,0
1,0,0,-2.1,0,0,GO:0055010,ventricular cardiac muscle tissue morphogenesis,M100,1,0
0,1,0,0,-3.8,0,GO:2000514,"regulation of CD4-positive, alpha-beta T cell activation",M010,1,0
1,0,0,-2.5,0,0,GO:0032418,lysosome localization,M100,1,0
1,0,0,-2.3,0,0,WP5094,Orexin receptor pathway,M100,1,0
0,1,0,0,-3.3,0,GO:0014743,regulation of muscle hypertrophy,M010,1,0
1,0,0,-2.9,0,0,GO:1903671,negative regulation of sprouting angiogenesis,M100,1,0
0,0,1,0,0,-2.1,GO:0001773,myeloid dendritic cell activation,M001,1,0
0,1,0,0,-2.4,0,GO:0060430,lung saccule development,M010,1,0
0,1,0,0,-2.3,0,GO:0010717,regulation of epithelial to mesenchymal transition,M010,1,0
1,0,0,-2.4,0,0,GO:1904894,positive regulation of receptor signaling pathway via STAT,M100,1,0
1,0,0,-2.9,0,0,WP5090,Complement system in neuronal development and plasticity,M100,1,0
1,0,0,-4.4,0,0,hsa05226,Gastric cancer,M100,1,0
0,1,0,0,-2,0,WP4970,Galanin receptor pathway,M010,1,0
1,0,0,-2.5,0,0,GO:0097035,regulation of membrane lipid distribution,M100,1,0
1,0,0,-4,0,0,GO:0048660,regulation of smooth muscle cell proliferation,M100,1,0
0,1,0,0,-2.5,0,GO:1904936,interneuron migration,M010,1,0
1,0,0,-3,0,0,WP4321,Thermogenesis,M100,1,0
0,1,0,0,-3,0,GO:0061326,renal tubule development,M010,1,0
0,1,0,0,-3.3,0,GO:0071875,adrenergic receptor signaling pathway,M010,1,0
0,0,1,0,0,-3.1,GO:0050817,coagulation,M001,1,0
0,1,0,0,-2.2,0,WP306,Focal adhesion,M010,1,0
0,1,0,0,-2.4,0,GO:0072289,metanephric nephron tubule formation,M010,1,0
1,0,0,-2.4,0,0,hsa04916,Melanogenesis,M100,1,0
0,1,0,0,-2.4,0,WP4549,Fragile X syndrome,M010,1,0
0,1,0,0,-2.7,0,GO:0099177,regulation of trans-synaptic signaling,M010,1,0
1,0,0,-3.2,0,0,GO:0140888,interferon-mediated signaling pathway,M100,1,0
1,0,0,-2.9,0,0,R-HSA-9670439,"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",M100,1,0
0,1,0,0,-2.8,0,CORUM:443,BP-SMAD complex,M010,1,0
1,0,0,-2.3,0,0,GO:1903578,regulation of ATP metabolic process,M100,1,0
1,0,0,-2.8,0,0,GO:0001779,natural killer cell differentiation,M100,1,0
1,0,0,-2.1,0,0,R-HSA-9818032,NFE2L2 regulating MDR associated enzymes,M100,1,0
0,0,1,0,0,-2.6,R-HSA-9683610,Maturation of nucleoprotein,M001,1,0
1,0,0,-4.1,0,0,WP2034,Leptin signaling pathway,M100,1,0
0,1,0,0,-2,0,GO:0002532,production of molecular mediator involved in inflammatory response,M010,1,0
0,1,0,0,-2.7,0,M234,PID IL2 STAT5 PATHWAY,M010,1,0
1,0,0,-3.3,0,0,GO:0097696,receptor signaling pathway via STAT,M100,1,0
0,1,0,0,-3.4,0,GO:0002431,Fc receptor mediated stimulatory signaling pathway,M010,1,0
0,0,1,0,0,-2.2,R-HSA-9716542,"Signaling by Rho GTPases, Miro GTPases and RHOBTB3",M001,1,0
1,0,0,-3,0,0,WP5353,A network map of Macrophage stimulating protein MSP signaling,M100,1,0
0,1,0,0,-4.1,0,R-HSA-2173796,SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription,M010,1,0
0,1,0,0,-2.9,0,GO:1901741,positive regulation of myoblast fusion,M010,1,0
0,1,0,0,-2.4,0,GO:0098916,anterograde trans-synaptic signaling,M010,1,0
0,0,1,0,0,-3.1,R-HSA-197264,Nicotinamide salvaging,M001,1,0
1,0,0,-3.3,0,0,GO:0007259,receptor signaling pathway via JAK-STAT,M100,1,0
1,0,0,-2.4,0,0,GO:0033500,carbohydrate homeostasis,M100,1,0
1,0,0,-2.2,0,0,GO:0010712,regulation of collagen metabolic process,M100,1,0
1,0,0,-3.2,0,0,M135,PID IL5 PATHWAY,M100,1,0
1,0,0,-2.2,0,0,hsa05332,Graft-versus-host disease,M100,1,0
1,0,0,-2.5,0,0,WP5269,Genetic causes of porto sinusoidal vascular disease,M100,1,0
0,1,0,0,-2,0,GO:0031077,post-embryonic camera-type eye development,M010,1,0
0,1,0,0,-2.5,0,GO:0072282,metanephric nephron tubule morphogenesis,M010,1,0
1,0,0,-3.5,0,0,hsa04925,Aldosterone synthesis and secretion,M100,1,0
1,0,0,-2.2,0,0,WP536,Calcium regulation in cardiac cells,M100,1,0
0,1,0,0,-2,0,GO:0040008,regulation of growth,M010,1,0
0,1,0,0,-2.9,0,GO:0014902,myotube differentiation,M010,1,0
1,0,0,-2.8,0,0,WP2263,Androgen receptor network in prostate cancer,M100,1,0
0,1,0,0,-2.4,0,WP4582,Cancer immunotherapy by CTLA4 blockade,M010,1,0
0,1,0,0,-4.4,0,GO:0050730,regulation of peptidyl-tyrosine phosphorylation,M010,1,0
0,1,0,0,-3.2,0,GO:0032956,regulation of actin cytoskeleton organization,M010,1,0
1,0,0,-2.3,0,0,GO:0043406,positive regulation of MAP kinase activity,M100,1,0
0,0,1,0,0,-5.2,GO:0042060,wound healing,M001,1,0
1,0,0,-2.2,0,0,R-HSA-201556,Signaling by ALK,M100,1,0
0,1,0,0,-4.1,0,GO:0032653,regulation of interleukin-10 production,M010,1,0
0,0,1,0,0,-2,GO:0031346,positive regulation of cell projection organization,M001,1,0
1,0,0,-2.4,0,0,GO:0007272,ensheathment of neurons,M100,1,0
0,0,1,0,0,-2.2,CORUM:2084,NFKB1-NFKB2-REL-RELA-RELB complex,M001,1,0
1,0,0,-2.5,0,0,hsa05222,Small cell lung cancer,M100,1,0
1,0,0,-2.6,0,0,GO:0000436,carbon catabolite activation of transcription from RNA polymerase II promoter,M100,1,0
0,1,0,0,-2.5,0,GO:0098581,detection of external biotic stimulus,M010,1,0
0,1,0,0,-5,0,GO:0042692,muscle cell differentiation,M010,1,0
1,0,0,-2.1,0,0,GO:0048002,antigen processing and presentation of peptide antigen,M100,1,0
1,0,0,-3.4,0,0,GO:0016055,Wnt signaling pathway,M100,1,0
0,1,0,0,-2.4,0,GO:0002690,positive regulation of leukocyte chemotaxis,M010,1,0
0,1,0,0,-3.3,0,GO:0097529,myeloid leukocyte migration,M010,1,0
0,1,0,0,-2.6,0,R-HSA-202433,Generation of second messenger molecules,M010,1,0
0,0,1,0,0,-2.1,GO:0048557,embryonic digestive tract morphogenesis,M001,1,0
0,0,1,0,0,-2.6,GO:0061030,epithelial cell differentiation involved in mammary gland alveolus development,M001,1,0
1,0,0,-2.5,0,0,GO:0070741,response to interleukin-6,M100,1,0
0,1,0,0,-2,0,GO:0072011,glomerular endothelium development,M010,1,0
0,1,0,0,-2.4,0,GO:0070673,response to interleukin-18,M010,1,0
1,0,0,-2.3,0,0,GO:0032088,negative regulation of NF-kappaB transcription factor activity,M100,1,0
0,1,0,0,-2,0,GO:0007512,adult heart development,M010,1,0
0,1,0,0,-3,0,GO:0001657,ureteric bud development,M010,1,0
1,0,0,-2.5,0,0,hsa04714,Thermogenesis,M100,1,0
1,0,0,-4.9,0,0,WP2324,AGE RAGE pathway,M100,1,0
1,0,0,-3.2,0,0,GO:0045778,positive regulation of ossification,M100,1,0
0,0,1,0,0,-2.1,GO:0002526,acute inflammatory response,M001,1,0
0,1,0,0,-2.3,0,GO:0048745,smooth muscle tissue development,M010,1,0
1,0,0,-2.7,0,0,M50,PID PTP1B PATHWAY,M100,1,0
1,0,0,-3.2,0,0,M66,PID MYC ACTIV PATHWAY,M100,1,0
1,0,0,-3.6,0,0,GO:0021675,nerve development,M100,1,0
1,0,0,-3.6,0,0,GO:0048771,tissue remodeling,M100,1,0
0,1,0,0,-2.8,0,GO:0106030,neuron projection fasciculation,M010,1,0
0,1,0,0,-2.5,0,GO:0072109,glomerular mesangium development,M010,1,0
1,0,0,-2.4,0,0,GO:0035024,negative regulation of Rho protein signal transduction,M100,1,0
1,0,0,-2.9,0,0,hsa04933,AGE-RAGE signaling pathway in diabetic complications,M100,1,0
1,0,0,-4,0,0,M288,PID HES HEY PATHWAY,M100,1,0
1,0,0,-2.7,0,0,GO:0045834,positive regulation of lipid metabolic process,M100,1,0
0,0,1,0,0,-2.8,M193,PID NEPHRIN NEPH1 PATHWAY,M001,1,0
0,1,0,0,-2,0,R-HSA-198693,AKT phosphorylates targets in the nucleus,M010,1,0
0,1,0,0,-4.2,0,GO:0060509,type I pneumocyte differentiation,M010,1,0
1,0,0,-2.9,0,0,GO:0090090,negative regulation of canonical Wnt signaling pathway,M100,1,0
0,1,0,0,-2.1,0,GO:0001738,morphogenesis of a polarized epithelium,M010,1,0
1,0,0,-3.7,0,0,GO:0045588,positive regulation of gamma-delta T cell differentiation,M100,1,0
0,1,0,0,-2,0,GO:0030518,intracellular steroid hormone receptor signaling pathway,M010,1,0
0,1,0,0,-2,0,R-HSA-9645460,Alpha-protein kinase 1 signaling pathway,M010,1,0
0,1,0,0,-2.5,0,WP391,Mitochondrial gene expression,M010,1,0
1,0,0,-2.9,0,0,GO:0070102,interleukin-6-mediated signaling pathway,M100,1,0
1,0,0,-3.7,0,0,GO:0048857,neural nucleus development,M100,1,0
1,0,0,-2.6,0,0,GO:0097012,response to granulocyte macrophage colony-stimulating factor,M100,1,0
0,1,0,0,-2.3,0,GO:0032675,regulation of interleukin-6 production,M010,1,0
0,1,0,0,-2.1,0,GO:0001954,positive regulation of cell-matrix adhesion,M010,1,0
1,0,0,-3.3,0,0,GO:0002444,myeloid leukocyte mediated immunity,M100,1,0
1,0,0,-2.4,0,0,GO:0007613,memory,M100,1,0
1,0,0,-4.3,0,0,GO:0016525,negative regulation of angiogenesis,M100,1,0
0,1,0,0,-3.8,0,GO:1904018,positive regulation of vasculature development,M010,1,0
0,1,0,0,-2.2,0,GO:0060993,kidney morphogenesis,M010,1,0
1,0,0,-2.6,0,0,WP2637,Interleukin 1 IL 1 structural pathway,M100,1,0
0,1,0,0,-2.9,0,GO:2000741,positive regulation of mesenchymal stem cell differentiation,M010,1,0
1,0,0,-2.2,0,0,hsa05164,Influenza A,M100,1,0
1,0,0,-2.2,0,0,GO:0032507,maintenance of protein location in cell,M100,1,0
1,0,0,-2.6,0,0,GO:0046016,positive regulation of transcription by glucose,M100,1,0
1,0,0,-3.9,0,0,GO:0031668,cellular response to extracellular stimulus,M100,1,0
1,0,0,-2.5,0,0,GO:0090132,epithelium migration,M100,1,0
1,0,0,-4.7,0,0,R-HSA-2990846,SUMOylation,M100,1,0
1,0,0,-4,0,0,GO:1904892,regulation of receptor signaling pathway via STAT,M100,1,0
1,0,0,-2.1,0,0,WP1559,Transcription factors regulate miRNAs related to cardiac hypertrophy,M100,1,0
0,1,0,0,-3.9,0,GO:0061009,common bile duct development,M010,1,0
1,0,0,-5.2,0,0,GO:0010633,negative regulation of epithelial cell migration,M100,1,0
0,1,0,0,-2.1,0,GO:0070374,positive regulation of ERK1 and ERK2 cascade,M010,1,0
1,0,0,-2,0,0,GO:0060740,prostate gland epithelium morphogenesis,M100,1,0
1,0,0,-3.8,0,0,hsa04371,Apelin signaling pathway,M100,1,0
0,0,1,0,0,-2.3,GO:0002069,columnar/cuboidal epithelial cell maturation,M001,1,0
1,0,0,-5.3,0,0,GO:0048048,embryonic eye morphogenesis,M100,1,0
1,0,0,-4.4,0,0,WP4541,Hippo Merlin signaling dysregulation,M100,1,0
0,1,0,0,-2.4,0,GO:0072174,metanephric tubule formation,M010,1,0
0,1,0,0,-2.4,0,WP4172,PI3K Akt signaling pathway,M010,1,0
0,1,0,0,-2.5,0,GO:0072173,metanephric tubule morphogenesis,M010,1,0
0,1,0,0,-2,0,GO:0071801,regulation of podosome assembly,M010,1,0
1,0,0,-2.2,0,0,GO:0051153,regulation of striated muscle cell differentiation,M100,1,0
0,1,0,0,-2,0,GO:0048866,stem cell fate specification,M010,1,0
0,1,0,0,-2.7,0,GO:1902253,regulation of intrinsic apoptotic signaling pathway by p53 class mediator,M010,1,0
0,1,0,0,-2.4,0,GO:0050852,T cell receptor signaling pathway,M010,1,0
1,0,0,-3.1,0,0,GO:1903557,positive regulation of tumor necrosis factor superfamily cytokine production,M100,1,0
1,0,0,-4.3,0,0,hsa04022,cGMP-PKG signaling pathway,M100,1,0
0,1,0,0,-2.6,0,GO:2000116,regulation of cysteine-type endopeptidase activity,M010,1,0
1,0,0,-2.2,0,0,GO:0017015,regulation of transforming growth factor beta receptor signaling pathway,M100,1,0
1,0,0,-2.1,0,0,R-HSA-1170546,Prolactin receptor signaling,M100,1,0
0,1,0,0,-3.3,0,GO:0008015,blood circulation,M010,1,0
1,0,0,-2.4,0,0,GO:0045604,regulation of epidermal cell differentiation,M100,1,0
0,1,0,0,-2,0,GO:0045628,regulation of T-helper 2 cell differentiation,M010,1,0
1,0,0,-2.7,0,0,GO:0019884,antigen processing and presentation of exogenous antigen,M100,1,0
1,0,0,-3.2,0,0,GO:0098868,bone growth,M100,1,0
1,0,0,-3.2,0,0,R-HSA-1433557,Signaling by SCF-KIT,M100,1,0
1,0,0,-2.3,0,0,hsa04211,Longevity regulating pathway,M100,1,0
1,0,0,-2.6,0,0,GO:0030901,midbrain development,M100,1,0
0,0,1,0,0,-2.6,GO:0030222,eosinophil differentiation,M001,1,0
0,0,1,0,0,-2.3,GO:1902882,regulation of response to oxidative stress,M001,1,0
0,1,0,0,-2,0,GO:0006468,protein phosphorylation,M010,1,0
1,0,0,-2.8,0,0,WP4698,Vitamin D sensitive calcium signaling in depression,M100,1,0
1,0,0,-2.9,0,0,GO:0048008,platelet-derived growth factor receptor signaling pathway,M100,1,0
0,1,0,0,-3,0,GO:0046639,negative regulation of alpha-beta T cell differentiation,M010,1,0
1,0,0,-2.1,0,0,GO:1904752,regulation of vascular associated smooth muscle cell migration,M100,1,0
1,0,0,-3.2,0,0,WP5397,Vitamin A1 and A5 X pathways,M100,1,0
0,1,0,0,-2.3,0,GO:0045063,T-helper 1 cell differentiation,M010,1,0
0,1,0,0,-4.4,0,GO:0044057,regulation of system process,M010,1,0
1,0,0,-2.7,0,0,hsa04917,Prolactin signaling pathway,M100,1,0
0,0,1,0,0,-3.6,GO:0060216,definitive hemopoiesis,M001,1,0
0,1,0,0,-2.7,0,GO:0071230,cellular response to amino acid stimulus,M010,1,0
0,1,0,0,-2.8,0,R-HSA-9637628,Modulation by Mtb of host immune system,M010,1,0
0,1,0,0,-2.4,0,GO:0060428,lung epithelium development,M010,1,0
1,0,0,-4.2,0,0,GO:0021756,striatum development,M100,1,0
0,1,0,0,-2.3,0,GO:0048708,astrocyte differentiation,M010,1,0
1,0,0,-3.1,0,0,hsa05212,Pancreatic cancer,M100,1,0
1,0,0,-2.3,0,0,GO:2000144,positive regulation of DNA-templated transcription initiation,M100,1,0
1,0,0,-3.1,0,0,GO:0002066,columnar/cuboidal epithelial cell development,M100,1,0
0,0,1,0,0,-2.2,M48,PID MET PATHWAY,M001,1,0
1,0,0,-4.6,0,0,GO:0048384,retinoic acid receptor signaling pathway,M100,1,0
1,0,0,-2.8,0,0,hsa04514,Cell adhesion molecules,M100,1,0
1,0,0,-5.4,0,0,GO:0002244,hematopoietic progenitor cell differentiation,M100,1,0
1,0,0,-3,0,0,GO:0007626,locomotory behavior,M100,1,0
0,1,0,0,-2.9,0,GO:0035655,interleukin-18-mediated signaling pathway,M010,1,0
1,0,0,-2.4,0,0,R-HSA-1839124,FGFR1 mutant receptor activation,M100,1,0
1,0,0,-2.4,0,0,GO:0070099,regulation of chemokine-mediated signaling pathway,M100,1,0
0,1,0,0,-2.4,0,GO:0008037,cell recognition,M010,1,0
0,0,1,0,0,-2.1,M252,PID IL8 CXCR1 PATHWAY,M001,1,0
1,0,0,-2.2,0,0,R-HSA-74158,RNA Polymerase III Transcription,M100,1,0
1,0,0,-2.3,0,0,GO:0045913,positive regulation of carbohydrate metabolic process,M100,1,0
0,1,0,0,-3.8,0,GO:0072073,kidney epithelium development,M010,1,0
1,0,0,-4.3,0,0,GO:0035265,organ growth,M100,1,0
1,0,0,-2.4,0,0,WP4674,Head and neck squamous cell carcinoma,M100,1,0
1,0,0,-2.2,0,0,GO:1903305,regulation of regulated secretory pathway,M100,1,0
0,0,1,0,0,-2.8,GO:0032944,regulation of mononuclear cell proliferation,M001,1,0
0,0,1,0,0,-2,WP5395,Glycosaminoglycan synthesis in fibroblasts,M001,1,0
0,0,1,0,0,-3.3,GO:0007599,hemostasis,M001,1,0
1,0,0,-2.6,0,0,GO:0010631,epithelial cell migration,M100,1,0
0,1,0,0,-2.9,0,GO:0019935,cyclic-nucleotide-mediated signaling,M010,1,0
1,0,0,-2,0,0,WP4630,Measles virus infection,M100,1,0
1,0,0,-3.7,0,0,GO:0035023,regulation of Rho protein signal transduction,M100,1,0
0,1,0,0,-2.4,0,GO:0071447,cellular response to hydroperoxide,M010,1,0
0,1,0,0,-2.6,0,R-HSA-3858494,Beta-catenin independent WNT signaling,M010,1,0
0,0,1,0,0,-3.1,GO:0007596,blood coagulation,M001,1,0
0,1,0,0,-2.6,0,GO:0034764,positive regulation of transmembrane transport,M010,1,0
0,0,1,0,0,-2.1,GO:0090025,regulation of monocyte chemotaxis,M001,1,0
0,1,0,0,-3.8,0,R-HSA-195721,Signaling by WNT,M010,1,0
0,0,1,0,0,-3.5,R-HSA-9679506,SARS-CoV Infections,M001,1,0
0,1,0,0,-2.5,0,GO:0032656,regulation of interleukin-13 production,M010,1,0
0,1,0,0,-2,0,GO:0086014,atrial cardiac muscle cell action potential,M010,1,0
0,1,0,0,-2.1,0,GO:0071867,response to monoamine,M010,1,0
0,1,0,0,-3,0,GO:0008064,regulation of actin polymerization or depolymerization,M010,1,0
1,0,0,-3.3,0,0,M44,PID HIF2PATHWAY,M100,1,0
0,0,1,0,0,-2.1,GO:0051489,regulation of filopodium assembly,M001,1,0
1,0,0,-2.4,0,0,GO:0045686,negative regulation of glial cell differentiation,M100,1,0
0,0,1,0,0,-3.2,CORUM:2529,"LAT-PLC-gamma-1-p85-GRB2-CBL-VAV-SLP-76 signaling complex, C305 activated",M001,1,0
1,0,0,-3.2,0,0,GO:0060323,head morphogenesis,M100,1,0
1,0,0,-2.4,0,0,GO:0031960,response to corticosteroid,M100,1,0
0,0,1,0,0,-2.5,hsa00532,Glycosaminoglycan biosynthesis - chondroitin sulfate / dermatan sulfate,M001,1,0
1,0,0,-2.8,0,0,GO:0001570,vasculogenesis,M100,1,0
0,0,1,0,0,-3.1,WP4146,Macrophage markers,M001,1,0
0,1,0,0,-2.3,0,GO:0030834,regulation of actin filament depolymerization,M010,1,0
1,0,0,-3.3,0,0,GO:0030513,positive regulation of BMP signaling pathway,M100,1,0
0,0,1,0,0,-2.1,GO:0060392,negative regulation of SMAD protein signal transduction,M001,1,0
1,0,0,-2.5,0,0,R-HSA-1368108,"BMAL1:CLOCK,NPAS2 activates circadian gene expression",M100,1,0
0,0,1,0,0,-2.6,GO:1900015,regulation of cytokine production involved in inflammatory response,M001,1,0
0,1,0,0,-2.1,0,GO:0090190,positive regulation of branching involved in ureteric bud morphogenesis,M010,1,0
0,1,0,0,-2.9,0,GO:0035283,central nervous system segmentation,M010,1,0
1,0,0,-2.5,0,0,GO:0007009,plasma membrane organization,M100,1,0
0,1,0,0,-2.5,0,GO:0060675,ureteric bud morphogenesis,M010,1,0
1,0,0,-2.1,0,0,hsa04725,Cholinergic synapse,M100,1,0
1,0,0,-3,0,0,GO:0097305,response to alcohol,M100,1,0
1,0,0,-3.6,0,0,GO:0006140,regulation of nucleotide metabolic process,M100,1,0
1,0,0,-2.4,0,0,M5193,SIG CHEMOTAXIS,M100,1,0
0,0,1,0,0,-2.4,hsa05231,Choline metabolism in cancer,M001,1,0
1,0,0,-2.4,0,0,GO:1903531,negative regulation of secretion by cell,M100,1,0
0,1,0,0,-2.4,0,GO:0060795,cell fate commitment involved in formation of primary germ layer,M010,1,0
1,0,0,-2.4,0,0,GO:0061377,mammary gland lobule development,M100,1,0
0,1,0,0,-2,0,GO:0010616,negative regulation of cardiac muscle adaptation,M010,1,0
1,0,0,-2.8,0,0,WP2895,Differentiation of white and brown adipocyte,M100,1,0
0,1,0,0,-2.3,0,GO:0008016,regulation of heart contraction,M010,1,0
1,0,0,-2.8,0,0,GO:0055094,response to lipoprotein particle,M100,1,0
0,0,1,0,0,-2.3,GO:0031295,T cell costimulation,M001,1,0
1,0,0,-2.1,0,0,WP5235,Estradiol regulation in porto sinusoidal vascular disease,M100,1,0
0,1,0,0,-2.5,0,GO:0045623,negative regulation of T-helper cell differentiation,M010,1,0
1,0,0,-2.1,0,0,GO:0043516,"regulation of DNA damage response, signal transduction by p53 class mediator",M100,1,0
1,0,0,-2.2,0,0,M239,PID A6B1 A6B4 INTEGRIN PATHWAY,M100,1,0
1,0,0,-2.1,0,0,GO:0043627,response to estrogen,M100,1,0
1,0,0,-4.5,0,0,GO:0042789,mRNA transcription by RNA polymerase II,M100,1,0
1,0,0,-4.3,0,0,GO:1901343,negative regulation of vasculature development,M100,1,0
0,1,0,0,-2.4,0,GO:0014074,response to purine-containing compound,M010,1,0
0,0,1,0,0,-2.3,WP4787,Osteoblast differentiation and related diseases,M001,1,0
1,0,0,-3.2,0,0,GO:0019886,antigen processing and presentation of exogenous peptide antigen via MHC class II,M100,1,0
0,1,0,0,-2.1,0,GO:0051896,regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction,M010,1,0
0,1,0,0,-2.2,0,GO:0002822,regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains,M010,1,0
0,1,0,0,-2.3,0,GO:0140352,export from cell,M010,1,0
0,1,0,0,-2.7,0,GO:0030859,polarized epithelial cell differentiation,M010,1,0
1,0,0,-3.2,0,0,GO:0046580,negative regulation of Ras protein signal transduction,M100,1,0
1,0,0,-5,0,0,GO:0045787,positive regulation of cell cycle,M100,1,0
0,1,0,0,-2,0,GO:0072008,glomerular mesangial cell differentiation,M010,1,0
1,0,0,-3.1,0,0,GO:1901655,cellular response to ketone,M100,1,0
1,0,0,-2.4,0,0,GO:0045185,maintenance of protein location,M100,1,0
0,1,0,0,-2,0,GO:0032729,positive regulation of type II interferon production,M010,1,0
1,0,0,-3.3,0,0,WP4482,Vitamin D in inflammatory diseases,M100,1,0
0,1,0,0,-3.3,0,GO:0048639,positive regulation of developmental growth,M010,1,0
0,1,0,0,-2,0,GO:0086066,atrial cardiac muscle cell to AV node cell communication,M010,1,0
0,1,0,0,-2.9,0,GO:0045937,positive regulation of phosphate metabolic process,M010,1,0
0,1,0,0,-2.2,0,GO:0010944,negative regulation of transcription by competitive promoter binding,M010,1,0
0,1,0,0,-2.5,0,GO:0003272,endocardial cushion formation,M010,1,0
1,0,0,-2.8,0,0,GO:0046847,filopodium assembly,M100,1,0
1,0,0,-3,0,0,M40,PID E2F PATHWAY,M100,1,0
1,0,0,-3.7,0,0,GO:0062197,cellular response to chemical stress,M100,1,0
0,1,0,0,-3.1,0,R-HSA-9006936,Signaling by TGFB family members,M010,1,0
1,0,0,-2.1,0,0,GO:0032933,SREBP signaling pathway,M100,1,0
0,1,0,0,-2.7,0,GO:0044092,negative regulation of molecular function,M010,1,0
0,1,0,0,-2,0,WP4884,Pathogenesis of SARS CoV 2 mediated by nsp9 nsp10 complex,M010,1,0
1,0,0,-3.1,0,0,WP2037,Prolactin signaling pathway,M100,1,0
0,1,0,0,-2.6,0,WP5284,Cell interactions of the pancreatic cancer microenvironment,M010,1,0
1,0,0,-2.3,0,0,hsa05230,Central carbon metabolism in cancer,M100,1,0
0,1,0,0,-4.8,0,GO:0030335,positive regulation of cell migration,M010,1,0
1,0,0,-2.1,0,0,GO:1903351,cellular response to dopamine,M100,1,0
1,0,0,-3.4,0,0,GO:0002503,peptide antigen assembly with MHC class II protein complex,M100,1,0
1,0,0,-7.2,0,0,GO:0071383,cellular response to steroid hormone stimulus,M100,1,0
0,0,1,0,0,-2,GO:0001893,maternal placenta development,M001,1,0
1,0,0,-2.8,0,0,WP581,EPO receptor signaling,M100,1,0
0,1,0,0,-3.9,0,GO:0032753,positive regulation of interleukin-4 production,M010,1,0
1,0,0,-4.4,0,0,WP1544,MicroRNAs in cardiomyocyte hypertrophy,M100,1,0
0,1,0,0,-2.3,0,GO:0110053,regulation of actin filament organization,M010,1,0
0,1,0,0,-2.7,0,GO:2000515,"negative regulation of CD4-positive, alpha-beta T cell activation",M010,1,0
1,0,0,-3.2,0,0,GO:0002504,antigen processing and presentation of peptide or polysaccharide antigen via MHC class II,M100,1,0
1,0,0,-2.6,0,0,GO:0045059,positive thymic T cell selection,M100,1,0
0,1,0,0,-2.5,0,GO:0002443,leukocyte mediated immunity,M010,1,0
0,0,1,0,0,-3.2,R-HSA-389359,CD28 dependent Vav1 pathway,M001,1,0
1,0,0,-2.6,0,0,GO:0035878,nail development,M100,1,0
1,0,0,-3.2,0,0,GO:0031663,lipopolysaccharide-mediated signaling pathway,M100,1,0
0,0,1,0,0,-3.3,M206,PID PDGFRA PATHWAY,M001,1,0
1,0,0,-3.6,0,0,GO:2000178,negative regulation of neural precursor cell proliferation,M100,1,0
1,0,0,-3.3,0,0,GO:0010171,body morphogenesis,M100,1,0
1,0,0,-3.2,0,0,GO:0045991,carbon catabolite activation of transcription,M100,1,0
0,0,1,0,0,-2.4,GO:0042733,embryonic digit morphogenesis,M001,1,0
1,0,0,-2.8,0,0,GO:0071354,cellular response to interleukin-6,M100,1,0
1,0,0,-2.3,0,0,hsa04932,Non-alcoholic fatty liver disease,M100,1,0
0,0,1,0,0,-2.4,GO:0045661,regulation of myoblast differentiation,M001,1,0
1,0,0,-3.3,0,0,M55,PID S1P S1P3 PATHWAY,M100,1,0
0,1,0,0,-2,0,GO:0048842,positive regulation of axon extension involved in axon guidance,M010,1,0
0,0,1,0,0,-4.6,GO:0021892,cerebral cortex GABAergic interneuron differentiation,M001,1,0
0,1,0,0,-2.1,0,R-HSA-202403,TCR signaling,M010,1,0
1,0,0,-2,0,0,R-HSA-452723,Transcriptional regulation of pluripotent stem cells,M100,1,0
0,1,0,0,-2.2,0,GO:0018212,peptidyl-tyrosine modification,M010,1,0
1,0,0,-2.1,0,0,GO:1901992,positive regulation of mitotic cell cycle phase transition,M100,1,0
0,1,0,0,-2.5,0,GO:1901739,regulation of myoblast fusion,M010,1,0
0,1,0,0,-2,0,WP5044,Kynurenine pathway and links to cell senescence,M010,1,0
0,1,0,0,-2,0,GO:0030575,nuclear body organization,M010,1,0
1,0,0,-2.1,0,0,hsa04911,Insulin secretion,M100,1,0
1,0,0,-2.1,0,0,GO:2000634,regulation of primary miRNA processing,M100,1,0
1,0,0,-3.6,0,0,GO:0060037,pharyngeal system development,M100,1,0
1,0,0,-2.1,0,0,GO:0046068,cGMP metabolic process,M100,1,0
0,1,0,0,-2.3,0,GO:0031018,endocrine pancreas development,M010,1,0
1,0,0,-2.1,0,0,GO:0030858,positive regulation of epithelial cell differentiation,M100,1,0
0,0,1,0,0,-2,hsa04610,Complement and coagulation cascades,M001,1,0
0,1,0,0,-2.2,0,GO:0034762,regulation of transmembrane transport,M010,1,0
1,0,0,-2.9,0,0,GO:0045931,positive regulation of mitotic cell cycle,M100,1,0
1,0,0,-3.9,0,0,WP2435,Quercetin and Nf kB AP 1 induced apoptosis,M100,1,0
0,1,0,0,-2.5,0,GO:0030225,macrophage differentiation,M010,1,0
1,0,0,-3.1,0,0,WP1982,Sterol regulatory element binding proteins SREBP signaling,M100,1,0
0,1,0,0,-3,0,GO:0044706,multi-multicellular organism process,M010,1,0
1,0,0,-2.4,0,0,GO:0023019,signal transduction involved in regulation of gene expression,M100,1,0
1,0,0,-3.3,0,0,GO:0034599,cellular response to oxidative stress,M100,1,0
1,0,0,-2.2,0,0,GO:0042552,myelination,M100,1,0
1,0,0,-5.2,0,0,GO:0035019,somatic stem cell population maintenance,M100,1,0
0,0,1,0,0,-4.5,R-HSA-9012999,RHO GTPase cycle,M001,1,0
1,0,0,-2.3,0,0,GO:0009913,epidermal cell differentiation,M100,1,0
1,0,0,-2.4,0,0,GO:0002891,positive regulation of immunoglobulin mediated immune response,M100,1,0
0,1,0,0,-2,0,WP5181,Roles of ceramides in development of insulin resistance,M010,1,0
1,0,0,-2.1,0,0,GO:0045721,negative regulation of gluconeogenesis,M100,1,0
0,1,0,0,-2.5,0,GO:1901724,positive regulation of cell proliferation involved in kidney development,M010,1,0
1,0,0,-3.7,0,0,GO:0043584,nose development,M100,1,0
0,1,0,0,-2.4,0,GO:0060487,lung epithelial cell differentiation,M010,1,0
0,1,0,0,-3.3,0,GO:0051336,regulation of hydrolase activity,M010,1,0
1,0,0,-4.2,0,0,WP4018,Clear cell renal cell carcinoma pathways,M100,1,0
1,0,0,-2.4,0,0,R-HSA-5655302,Signaling by FGFR1 in disease,M100,1,0
0,1,0,0,-2,0,GO:0032736,positive regulation of interleukin-13 production,M010,1,0
1,0,0,-2.6,0,0,GO:0000429,carbon catabolite regulation of transcription from RNA polymerase II promoter,M100,1,0
1,0,0,-2.6,0,0,hsa05416,Viral myocarditis,M100,1,0
1,0,0,-3.6,0,0,GO:0048596,embryonic camera-type eye morphogenesis,M100,1,0
1,0,0,-2.4,0,0,GO:0042593,glucose homeostasis,M100,1,0
1,0,0,-2.6,0,0,GO:1990830,cellular response to leukemia inhibitory factor,M100,1,0
1,0,0,-2,0,0,R-HSA-9619665,EGR2 and SOX10-mediated initiation of Schwann cell myelination,M100,1,0
1,0,0,-2.2,0,0,R-HSA-749476,RNA Polymerase III Abortive And Retractive Initiation,M100,1,0
1,0,0,-2.4,0,0,WP5063,FOXP3 in COVID 19,M100,1,0
0,1,0,0,-2,0,GO:0071697,ectodermal placode morphogenesis,M010,1,0
0,1,0,0,-2.2,0,GO:0021610,facial nerve morphogenesis,M010,1,0
0,1,0,0,-3.7,0,GO:0003013,circulatory system process,M010,1,0
1,0,0,-2.4,0,0,GO:0043586,tongue development,M100,1,0
1,0,0,-2.5,0,0,WP5348,11p11 2 copy number variation syndrome,M100,1,0
1,0,0,-2.9,0,0,M105,PID TELOMERASE PATHWAY,M100,1,0
1,0,0,-2.8,0,0,GO:0043303,mast cell degranulation,M100,1,0
0,1,0,0,-2.2,0,GO:1901222,regulation of non-canonical NF-kappaB signal transduction,M010,1,0
0,1,0,0,-2,0,R-HSA-9708530,Regulation of BACH1 activity,M010,1,0
0,1,0,0,-3.3,0,GO:0032819,positive regulation of natural killer cell proliferation,M010,1,0
1,0,0,-3.4,0,0,WP395,IL 4 signaling pathway,M100,1,0
1,0,0,-2,0,0,GO:0043542,endothelial cell migration,M100,1,0
